f hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report finance brief key results sales core operating profit margin cer growth sales pharmaceuticals diagnostics group change sales chf chf chf cer ifrs results sales operating profit net income net income attributable roche shareholders diluted eps chf dividend per share chf core results research development core operating profit core eps chf free cash flow operating free cash flow free cash flow change chf chf chf cer net debt capitalisation debt equity proposed board directors cer constant exchange rates percentage changes constant exchange rates calculated using simulations reconsolidating results constant exchange rates average rates year ended december definition cer see core results core eps earnings per share exclude noncore items global restructuring plans amortisation impairment goodwill intangible assets allows assessment actual results underlying performance business full income statement group operating results divisions shown ifrs core basis core concept fully described pages reconciliations ifrs core results given free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business free cash flow concept fully described pages reconciliations ifrs cash flow free cash flow given therefinance brief roche roche group reported good overall results sales core earnings per share grew constant exchange rates cer ifrs net income decreased due significant impairments goodwill intangible assets sales group sales increased cer chf billion growth chf terms pharmaceuticals sales growth cer due recently launched medicines ocrevus tecentriq alecensa oncology continued growth franchise sales avastin decreased due competitive pressure immunology sales increased led xolair actemraroactemra sales tamiflu fell due generic competition us entry biosimilars negative impact sales mabtherarituxan europe diagnostics sales showed growth cer immunodiagnostics business major contributor operating results core operating profit increased cer chf billion increase chf terms research development expenditure grew cer chf billion core basis focus oncology immunology therapeutic areas research development costs represented group sales ifrs operating results include noncore expenses pretax chf billion major factors chf billion impairment goodwill intangible assets chf billion amortisation intangible assets chf billion global restructuring plans notably pharmaceuticals divisions strategic realignment manufacturing network nonoperating results financing costs ifrs decreased chf billion chf billion driven lower interest expenses lower losses bond redemptions income tax expenses ifrs include transitional expenses chf billion arising changes us tax rates core effective tax rate net income ifrs net income decreased cer chf billion decrease chf terms core earnings per share increased cer chf terms cash flows operating free cash flow increased significantly chf billion underlying cash generation divisions lower net working capital lower capital expenditure led increase operating free cash flow cer chf terms free cash flow increased cer chf terms chf billion driven higher operating free cash flow well lower pension contributions lower interest paid financial position net working capital decreased cer due higher payables accrued liabilities lower inventories offset increase receivables driven increased sales net debt decreased chf billion generated free cash flow offset dividends paid net debt percentage total assets credit ratings strong moodys standard poors aa shareholder return dividends proposal made increase dividends chf per share represent st consecutive year dividend growth result payout ratio subject agm approval total shareholder return tsr representing combined performance share nonvoting equity securityroche group finance brief inside cover finance brief financial review roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles noncurrent liabilities operating segment information current liabilities net financial expense provisions contingent liabilities income taxes debt business combinations equity attributable roche shareholders global restructuring plans subsidiaries associates property plant equipment noncontrolling interests goodwill employee benefits intangible assets pensions postemployment benefits inventories equity compensation plans accounts receivable earnings per share nonvoting equity security marketable securities statement cash flows cash cash equivalents risk management noncurrent assets related parties current assets list subsidiaries associates accounts payable significant accounting policies report roche management internal control financial reporting statutory auditors report general meeting roche holding ltd basel independent reasonable assurance report internal control financial reporting multiyear overview supplementary information roche securities roche holding ltd basel financial statements notes financial statements appropriation available earnings statutory auditors report general meeting roche holding ltd basel financial review roche group financial review roche group results sales billions chf core operating profit billions chf cer growth sales net income attributable roche shareholders billions chf core eps chf roche groups results showed sales growth constant exchange rates cer core operating profit core eps sales growth driven recently launched pharmaceuticals products ocrevus tecentriq alecensa immunodiagnostics business diagnostics division group continued supporting development launch new products reported growth core operating profit despite base effect income pension changes results operating free cash flow chf billion increase due cash generated business coupled decrease net working capital lower capital expenditure sales pharmaceuticals division rose chf billion ocrevus tecentriq alecensa contributing chf billion new sales representing divisions growth oncology franchise sales increased chf billion led perjeta mabtherarituxan sales chf billion growth globally despite sales europe lower following biosimilar entry sales avastin chf billion decline due competitive pressure sales immunology grew chf billion xolair actemraroactemra increasing respectively sales tamiflu fell due competition generics us market diagnostics division sales grew major growth area centralised point care solutions sales increased led immunodiagnostics business ifrs operating profit stable pharmaceuticals division diagnostics division divisions impacted impairment charges goodwill intangible assets pharmaceuticals core operating profit increased diagnostics remained stable operating profit growth rates divisions impacted base effect income changes groups swiss pension plans pharmaceuticals marketing distribution costs grew due launch new products notably ocrevus tecentriq continued investment research development totalled chf billion group major areas pharmaceuticals oncology tecentriq cancer immunotherapy portfolio key drivers immunology neuroscience diagnostics activities increasingly focused integrated core laboratory digitalised data management projects division acquired viewics software company focused laboratory business analytics operating free cash flow chf billion increase chf billion due high cash generation business sales growth exceeding increases cash expenses furthermore net working capital decreased overall increase decrease mainly due higher payables partially offset higher receivables capital expenditure decreased well compared free cash flow chf billion increase chf billion due higher operating free cash flow lower pension contributions lower interest payments net income decreased cer ifrs basis increased core basis addition items described core results ifrs results include intangible asset impairment charges totalling chf billion notably chf billion partial impairment esbriet product intangible asset impairments diagnostics sequencing business chf billion roche finance report roche group financial review global restructuring expenses chf billion line expenses offsetting income chf billion reversal contingent consideration arrangements chf billion income release legal provisions financing costs lower due decreasing interest expenses lower losses bond redemptions changes us tax rates become effective january resulted transitional expense chf billion arising remeasurement groups yearend deferred tax positions core eps increased cer line sales growth compared swiss franc weaker euro european currencies several major currencies asiapacific region partially offset stronger swiss franc japanese yen swiss franc remained stable us dollar net impact negligible results expressed swiss francs compared constant exchange rates sales core operating profit core eps income statement change change chf chf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests eps basic chf eps diluted chf core results sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core eps basic chf core eps diluted chf see pages definition core results core eps roche finance report financial review roche group sales sales increased cer chf usd chf billion sales pharmaceuticals division rose chf billion growth oncology immunology neuroscience therapeutic areas key growth driver additional chf billion sales recently launched products ocrevus tecentriq alecensa three new products represented divisions growth already account divisions total sales mabtherarituxan sales chf billion growth driven us growth first biosimilar versions launched several eu markets contributed decrease mabtherarituxan sales europe sales avastin chf billion decline due competitive pressure franchise continued grow sales increasing main drivers growth increased global demand perjeta higher herceptin sales notably us immunology sales chf billion growth coming actemra roactemra xolair sales tamiflu fell due competition generics us market diagnostics division recorded sales chf billion increase major growth area centralised point care solutions represents divisions sales grew led immunodiagnostics business divisional operating results pharmaceuticals diagnostics corporate group chf chf chf chf sales core operating profit margin sales operating profit margin sales operating free cash flow margin sales divisional operating results development results compared pharmaceuticals diagnostics corporate group sales increase cer core operating profit increase cer margin percentage point increase operating profit increase cer margin percentage point increase operating free cash flow increase cer margin percentage point increase roche finance report roche group financial review core operating results core operating profit group increased cer pharmaceuticals division core operating profit increased diagnostics division stable chf billion income chf million pretax changes groups pension plans switzerland excluding item core operating profit group grew compared growth pharmaceuticals division diagnostics division pharmaceuticals division divisions core operating profit increased cer sales increase increased expenditure research development well launch expenses ocrevus tecentriq new products income product disposals income chf million compared chf million income pension plan changes chf million diagnostics division core operating profit stable cer increase pension changes excluded cost sales increased due unfavourable product mix arising higher instrument placements notably asiapacific region marketing distribution increased higher spending emerging markets especially china general administration increased due income pension changes base effect chf million acquisitions group acquired controlling interest mysugr gmbh developed one leading mobile diabetes platforms market total cash consideration chf million addition group acquired controlling interest viewics inc consideration chf million viewics software company focused laboratory business analytics december group announced agreement fully acquire ignyta inc total transaction value usd billion chf million noncore income contingent consideration provisions mainly due reversal remaining provision related seragon acquisition partial reversal provisions related dutalys trophos acquisitions impairment charges chf million related acquisitions noted impairment goodwill intangible assets commentary chf million noncore income contingent consideration provisions related intangible asset impairment charges chf million noncore costs also included expenses chf million release esbriet inventory fair value adjustment fully unwound mid details given notes annual financial statements global restructuring plans group initiated various resourcing flexibility plans pharmaceuticals division address various future challenges including biosimilar competition areas plans include biologics manufacturing commercial operations product development strategy group also continued implementation several major global restructuring plans initiated prior years notably strategic realignment pharmaceuticals divisions manufacturing network programmes address longterm strategy diagnostics division roche finance report financial review roche group global restructuring plans costs incurred millions chf diagnostics site consolidation plans total global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs includes strategy plans diagnostics division diabetes care autonomy speed plan includes pharmaceuticals divisions strategic realignment manufacturing network resourcing flexibility biologics manufacturing network includes plans resourcing flexibility pharmaceuticals divisions commercial operations global product developmentstrategy organisations diagnostics division strategy plans diagnostics division launched incurred costs chf million mainly employeerelated costs spending smaller plans within division chf million included costs related autonomy speed initiative diabetes care certain projects site consolidation november pharmaceuticals division announced strategic realignment manufacturing network including exiting manufacturing sites clarecastle ireland legans spain segrate italy florence us costs plan chf million chf million noncash writedowns accelerated depreciation property plant equipment employeerelated provisions reversed likely scenario segrate site changed closure divestment divestments florence segrate legans sites completed result total costs chf million includes chf million accumulated currency translation losses consolidation transferred income statement expected costs environmental remediation clarecastle site reassessed resulted increase provisions environmental remediation plans include resourcing flexibility biologics manufacturing network resulted headcount reductions us also kaiseraugst site switzerland exit small molecules manufacturing site toluca mexico global restructuring plans major item chf million resourcing flexibility pharmaceuticals division including global field force reductions notably us europe remaining chf million includes plans outsourcing functions shared service centres external providers details given note annual financial statements impairment goodwill intangible assets impairment charges chf million pharmaceuticals division largest item charge chf million partial impairment esbriet product intangible acquired part intermune acquisition impairment charge recorded first half intangible asset following lowerthanexpected sales esbriet first half relative recent longterm forecasts revised longterm forecasts prepared second half show reduction sales expectations resulted additional impairment charge charge chf million full writeoff goodwill relating seragon acquisition due decision stop development backup compound acquired addition impairment chf million relating compound acquired part trophos acquisition arising launch competitor product impairment chf million due decision stop development one compound alliance partner following assessment clinical nonclinical data related decrease contingent consideration provisions mainly seragon trophos dutalys acquisitions contributed income chf million noted acquisitions commentary roche finance report roche group financial review diagnostics division recorded impairment charges chf million major part sequencing business impairment charges chf million goodwill chf million product intangible assets acquired part ariosa acquisition impairments due latest longterm forecasts projecting decrease forecasted cash flows due changed assumptions around market penetration pricing reimbursement revised time market single molecule sequencing technology addition molecular diagnostics business partial impairment chf million also recorded product intangible assets acquired part geneweave acquisition also due decrease forecasted cash flows follows change timelines future product development updated market size assumptions details given notes annual financial statements pensions postemployment benefits operating income chf million recorded past service costs changes groups pension plans switzerland announced june represented onetime impact adjustment pension liability plan changes amount chf million recorded pharmaceuticals division chf million diagnostics division chf million corporate aftertax impact chf million matter base effect growth rates shown results information groups pensions postemployment benefits given note annual financial statements legal environmental cases based development various litigations notably accutane case provisions previously held released resulting income chf million expected costs environmental remediation clarecastle site ireland reassessed resulted increase provisions environmental remediation significant developments impacting financial results details given note annual financial statements treasury taxation core financing costs chf million decrease due lower interest expenses lower interest costs pension plans lower losses bond redemption core financial income chf million including net income equity securities chf million partly offset net foreign exchange losses chf million core tax expenses increased chf billion since lower increase profit tax groups effective core tax rate decreased compared largely due mix effects within manufacturing supply chain december changes us tax rates enacted become effective january among changes decrease us federal tax rate resulted transitional expense chf million arising remeasurement groups deferred tax positions treated noncore item new rates applied whole excluding transition impacts groups effective core tax rate percentage terms would low twenties roche finance report financial review roche group net income earnings per share ifrs net income decreased swiss franc terms cer diluted eps decreased swiss franc terms cer core net income increased core eps increased cer core basis excludes noncore items global restructuring costs amortisation impairment goodwill intangible assets alliance business combination costs core eps increased excluding base impact changes groups swiss pension plans net income change change chf chf chf cer ifrs net income reconciling items net tax global restructuring plans intangible asset amortisation goodwill intangible asset impairment alliances business combinations legal environmental cases pension plan settlements transitional effect changes us tax rates normalisation equity compensation plan tax benefit core net income supplementary net income eps information given pages includes calculations core eps reconciles core results groups published ifrs results financial position financial position change change chf chf chf cer pharmaceuticals net working capital longterm net operating assets diagnostics net working capital longterm net operating assets corporate net working capital longterm net operating assets net operating assets net debt pensions income taxes nonoperating assets net total net assets compared start year swiss franc depreciated significantly euro positive translation impact balance sheet positions appreciation swiss franc us dollar negative translation impact net operating assets mostly offset group level natural hedge groups us dollardenominated debt exchange rates used given roche finance report roche group financial review pharmaceuticals division net working capital decreased cer major driver higher liabilities sales rebates chargebacks another factor inventories writeoffs decrease inventory levels certain mature products partly offset higher inventories launch products offset increase trade receivables due higher sales extended postlaunch payment terms ocrevus us longterm net operating assets lower due chf billion impairments intangible assets diagnostics division decrease net working capital cer driven increase payables due higher liabilities pending rebates inventories decreased due inventories optimisation initiatives high demand decrease trade payables followed lower spending trade receivables increased due higher sales longterm net operating assets decreased due lower goodwill intangible assets partially offset higher property plant equipment lower provisions decrease net debt due free cash flow chf billion partly offset dividend payments chf billion net pension liability decreased chf billion chf billion due improved asset performance net tax liabilities decreased mainly due deferred tax impact impairment intangible assets partially offset deferred tax impact changes us tax rates announced late free cash flow free cash flow change change chf chf chf cer pharmaceuticals diagnostics corporate operating free cash flow treasury activities taxes paid free cash flow definition free cash flow detailed breakdown see pages groups operating free cash flow chf billion increase chf billion cer reflects higher cash generation business due improved operating results sales growth exceeding cash operating expenses development operating free cash flow also positively impacted net working capital decreased increase decrease mainly due higher payables partially offset higher receivables also base impact inventories buildup repeated contributed yearonyear growth operating free cash flow capital expenditure also lower comparative period free cash flow chf billion increase chf billion compared due higher operating free cash flow lower pension contributions lower interest payments roche finance report financial review roche group pharmaceuticals division operating results pharmaceuticals division operating results change change chf chf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results see pages definition free cash flow sales overview pharmaceuticals division sales therapeutic area change sales sales chf chf cer oncology immunology neuroscience ophthalmology infectious diseases therapeutic areas total sales pharmaceuticals division sales increased cer chf billion growth oncology immunology neuroscience therapeutic areas main products driving growth recently launched medicines ocrevus tecentriq alecensa contributed chf billion cer new sales three new products represented divisions growth already account divisions total sales significant growth drivers perjeta xolair actemraroactemra herceptin mabtherarituxan growth led immunology first biosimilar versions mabtherarituxan launched several eu markets mid led decreased sales europe avastin sales declined competitive pressure sales tamiflu fell due generic competition us roche finance report roche group financial review ocrevus launched us april good uptake sales chf billion growth tecentriq sales driven mainly uptake us metastatic urothelial carcinoma metastatic nonsmall cell lung cancer alecensa sales higher led us japan franchise continued grow sales increasing main driver growth increased global demand perjeta neoadjuvant metastatic settings herceptin sales higher notably us sales increases immunology came xolair us increasing use actemraroactemra us europe product sales pharmaceuticals division sales change sales sales chf chf cer oncology herceptin avastin mabtherarituxan perjeta kadcyla tarceva tecentriq xeloda alecensa gazyvagazyvaro others total oncology immunology actemraroactemra xolair mabtherarituxan esbriet pulmozyme cellcept others total immunology neuroscience ocrevus madopar others total neuroscience ophthalmology lucentis total ophthalmology infectious diseases tamiflu rocephin valcytecymevene pegasys others total infectious diseases therapeutic areas activasetnkase mircera neorecormonepogin others total therapeutic areas total sales total mabtherarituxan sales chf million chf million split oncology immunology franchises roche finance report financial review roche group mabtherarituxan nonhodgkin lymphoma nhl chronic lymphocytic leukaemia cll follicular lymphoma fl rheumatoid arthritis ra well certain types antineutrophil cytoplasmic antibody anca associated vasculitis mabtherarituxan regional sales change sales sales chf chf cer united states europe japan international total sales sales higher driven growth immunology segment us mabtherarituxan widely used across nearly approved indications sales increased sales also higher international region particularly brazil due higher government sales sales europe fell driven launch biosimilars several eu markets year franchise herceptin perjeta kadcyla herpositive breast cancer herpositive metastatic advanced gastric cancer herceptin herceptin regional sales change sales sales chf chf cer united states europe japan international total sales perjeta regional sales change sales sales chf chf cer united states europe japan international total sales kadcyla regional sales change sales sales chf chf cer united states europe japan international total sales franchise grew chf billion herceptin sales higher driven growth us mainly due continued growth early metastatic breast cancer also continued growth europe driven sales growth uk italy perjeta sales grew regions following increased demand neoadjuvant metastatic settings kadcyla sales increased us especially international region uptake turkey significant factor roche finance report roche group financial review avastin advanced colorectal breast lung kidney cervical ovarian cancer relapsed glioblastoma type brain tumour avastin regional sales change sales sales chf chf cer united states europe japan international total sales overall sales prior year us sales decreased due competition immunotherapy medicines lung cancer europe sales declined mainly driven delisting metastatic breast cancer france sales grew international region particular china sales increased due broader market penetration lung colorectal cancer setting japan sales increased due increasing volume growth partially offset negative impact biannual government price cuts actemraroactemra rheumatoid arthritis ra systemic juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis giant cell arteritis actemraroactemra regional sales change sales sales chf chf cer united states europe japan international total sales sales increased growth regions driven continued uptake subcutaneous formulation xolair moderate severe persistent allergic asthma aa chronic idiopathic urticaria ciu xolair regional sales change sales sales chf chf cer united states total sales sales grew driven market expansion outpacing competitive erosion allergic asthma continued growth chronic idiopathic urticaria ocrevus relapsing forms multiple sclerosis rms primary progressive multiple sclerosis ppms ocrevus regional sales change sales sales chf chf cer united states europe international total sales ocrevus approved sale us food drug administration fda march shown strong uptake since launched ocrevus approved european union rms ppms january roche finance report financial review roche group lucentis wet agerelated macular degeneration wet amd macular oedema following retinal vein occlusion rvo diabetic macular oedema dme lucentis regional sales change sales sales chf chf cer united states total sales sales increased us mainly driven launch prefilled syringes growth new indications diabetic retinopathy dr myopic choroidal neovascularisation mcnv activasetnkase acute ischaemic stroke ais acute myocardial infarction ami activasetnkase regional sales change sales sales chf chf cer united states international total sales sales higher led us mainly due increase penetration eligibility treatment centres tarceva advanced nonsmall cell lung nsclc pancreatic cancer tarceva regional sales change sales sales chf chf cer united states europe japan international total sales sales lower declining sales mainly us europe international region due increasing competitive pressure pharmaceuticals division sales region change sales sales chf chf cer united states europe japan international eemea latin america asiapacific regions total sales eastern europe middle east africa united states sales grew led uptake following launches ocrevus tecentriq xolair sales activase tnkase sales increased due patient uptake franchise mabtherarituxan also continued grow respectively tamiflu sales declined mainly due competition generics sales avastin fell due competition immunotherapy medicines lucentis sales broadly stable sales tarceva lower due competitive pressure mandatory discounts hospitals b drug discount program increased although lower rate mainly due higher utilisation oncology products roche finance report roche group financial review europe sales decreased mainly due lower mabtherarituxan sales driven competition biosimilar versions launched several eu markets franchise continued grow driven perjeta sales especially uk spain actemraroactemra sales increased due growing demand subcutaneous formulation avastin sales decreased primarily result delisting metastatic breast cancer france tamiflu sales europe lower due base effect governmental order uk japan sales grew alecensa sales increased due proceeded market penetration tamiflu actemra roactemra osteoporosis medicine edirol grew partially offset lower sales various established products international sales increased driven latin america asiapacific sales china mainly grew due additional reimbursement well broader market penetration avastin sales brazil increased led herceptin saw higher demand russia sales declined result competition noncomparable biologics herceptin pharmaceuticals division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales competition generic medicines biosimilars groups pharmaceutical products generally protected patent rights intended provide group exclusive marketing rights various countries however patent rights varying scope duration group may required enter costly litigation enforce patent intellectual property rights loss market exclusivity one major products either due patent expiration challenges generic medicines biosimilars noncomparable biologics reasons could material adverse effect groups business results operations financial condition introduction generic biosimilar noncomparable biologic version similar medicine typically results significant reduction net sales relevant product manufacturers typically offer versions lower prices patents expiry always integral part groups business model future growth remain driven innovation latest information clinical studies included annual report pages details groups product development portfolio available download httpwwwrochecomresearchanddevelopmentwhowearehowweworkpipelinehtm product sales affected recent patent expiry change chf chf cer comment tamiflu patent expiry us major markets pegasys us patent expiry major markets valcytecymevene us patent expiry major markets intellectual property biologics involve multiple patents patent timelines individual product therefore difficult give exact date patent expiry biologic medicines group currently estimates basic primary patents major biologic medicines begin expire follows mabtherarituxan around mid us herceptin mid us avastin mid us around eu subcutaneous formulations mabtherarituxan herceptin beyond secondary patent rights roche finance report financial review roche group composition matter patents mabtherarituxan herceptin eu expired first biosimilar versions mabtherarituxan launched several eu markets mid major driver sales decline europe product sales affected biosimilar launches change chf chf cer comment mabtherarituxan europe first biosimilar launches mid based publicly available information competitor companies group currently anticipates following potential developments us still many uncertainties surrounding specific biosimilar versions groups biologic medicines approved food drug administration first biosimilar versions mabtherarituxan could come market us around mid end europe first biosimilar versions herceptin could come market first half japan first biosimilar version mabtherarituxan approved listed late first biosimilar versions herceptin could also come market japan sales mabtherarituxan herceptin avastin disclosed previous sections including regional breakdowns operating results pharmaceuticals division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis increase cer mainly due higher income product disposals included sale worldwide rights bonviva bondronat excluding us japan dilatrend kytril excluding japan royalty income increased mainly due net increase sales across royalty portfolio partly offset expiration royalty bearing eylea patents income outlicensing agreements increased due outlicensing lebrikizumab rights pharmaceuticals division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses collaboration profitsharing agreements impairment property plant equipment cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets business combinations inventory fair value adjustment total ifrs basis core costs increased cer percentage sales cost sales increased percentage points manufacturing cost sales grew line sales growth increased costs new manufacturing facilities brought online recent years partly offset lower inventory writeoffs royalty expenses higher due ocrevus sales noncore costs include amortisation intangible assets mainly related esbriet product intangibles acquired intermune acquisition results additionally include chf million impairment esbriet intangibles due lower thanexpected sales esbriet reduction sales expectations latest longterm forecasts results included final fair value unwind adjustment chf million acquired esbriet inventories roche finance report roche group financial review pharmaceuticals division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer percentage sales remained stable costs incurred ensure increased patient access launches ocrevus tecentriq hemlibra products restructuring costs relate resourcing flexibility initiatives sales affiliates pharmaceuticals division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer percentage sales decreased percentage points oncology franchise remained primary area research development tecentriq cancer immunotherapy portfolio key drivers neuroscience immunology also significant areas spending earlystage research latestage development addition pharmaceuticals division inlicensed pipeline compounds technologies total value chf million chf million capitalised intangible assets impairment charges chf million include impairment chf million compound acquired part trophos acquisition arising launch competitor product impairment chf million due decision stop development one compound alliance partner following assessment clinical nonclinical data impairments totalling chf million recorded following writeoff intangible assets acquired dutalys santaris acquisitions pharmaceuticals division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets alliances business combinations legal environmental cases pensions settlement gains losses total ifrs basis core costs increased cer percentage sales increased due income pension changes chf million excluding core costs increased mainly due higher legal service costs also higher personnel costs across division impairments consist writeoff chf million goodwill due decision stop development backup compound acquired part seragon acquisition alliance business combination income includes reversal contingent consideration provisions seragon trophos dutalys acquisitions global restructuring costs primarily relate divestment florence segrate legans sites roche finance report financial review roche group roche pharmaceuticals chugai subdivisional operating results pharmaceuticals subdivisional operating results millions chf roche pharmaceuticals pharmaceuticals chugai division sales external customers within division core operating profit margin sales external customers operating profit margin sales external customers operating free cash flow margin sales pharmaceuticals division total core operating profit operating profit include elimination chf minus million unrealised intercompany gains roche pharmaceuticals chugai chf plus million decrease exchange rate japanese yen negative impact chugai results expressed swiss francs sales chugai third parties increased japanese yen sales within division increased japanese yen chugai core operating profit increased due higher sales milestone income partially offset increased research development costs higher general administration costs operating free cash flow chugai increased chf million due decrease inventories higher operating profit financial position pharmaceuticals division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow includes cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc appreciated us dollar resulting negative translation impact net operating assets partially offset positive translation impact euro swiss franc depreciated exchange rates used given roche finance report roche group financial review net working capital net working capital decreased due lower inventories higher net liability receivables payables inventories decreased due inventory writeoffs lower inventory levels certain mature products partly offset higher inventories launch products net liability receivablespayables increased due higher accruals sales rebates chargebacks payroll accrued liabilities also included chf million genentech property purchase option exercise obligation due july partially offsetting effects trade receivables increased due higher sales also due extended payment terms ocrevus us longterm net operating assets overall longterm net operating assets decreased goodwill intangible assets decreased due significant impairments recorded capital expenditure included manufacturing investments us germany chugai japan also site development basel kaiseraugst sites switzerland south san francisco campus provisions decreased following reversal contingent consideration legal provisions utilisation restructuring provisions longterm net assets increased due reclassification longterm shortterm chf million liabilities genentech property purchase option exercise obligation due july free cash flow pharmaceuticals division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales see pages definition free cash flow detailed breakdown pharmaceuticals divisions operating free cash flow increased chf billion main contribution came operating profit net operating cash adjustments increase cer higher increase core operating profit due base effect income pension changes net working capital absorbed less cash start year mainly due higher payables partially offset higher receivables reduction balance sheet inventories came noncash effective writedowns however buildup inventories occurred repeated contributed yearonyear growth operating free cash flow capital expenditure chf billion major items described financial position section capital expenditure investments intangible assets lower contributed yearonyear growth operating free cash flow roche finance report financial review roche group diagnostics division operating results diagnostics division operating results change change chf chf chf cer ifrs results sales royalties operating income cost sales marketing distribution research development general administration operating profit margin sales core results sales royalties operating income cost sales marketing distribution research development general administration core operating profit margin sales financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow margin sales see pages definition core results see pages definition free cash flow sales diagnostics division continued increase sales growth cer chf billion centralised point care solutions sales growth main contributor led immunodiagnostics business molecular diagnostics sales increased mainly driven biochemical reagents molecular diagnostics instruments human papillomavirus hpv screening diabetes care sales decreased due continued challenging market conditions us growth tissue diagnostics driven advanced staining product portfolio diagnostics division sales business area change sales sales chf chf cer centralised point care solutions diabetes care molecular diagnostics tissue diagnostics total sales roche finance report roche group financial review centralised point care solutions increase sales business area major contributor divisional sales performance growth primarily driven immunodiagnostics business represented divisional sales sales growth also supported clinical chemistry business regionally sales grew asiapacific due growth china sales growth reported europe middle east africa emea region mainly due immunodiagnostics business centralised point care solutions regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales diabetes care sales decreased due continuation challenging market conditions us leading decline north america sales decrease emea due competitive pressure increasing reimbursement competitor systems continuous glucose monitoring notably germany sales growth rest world driven new business latin america argentina brazil asiapacific china india diabetes care regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales molecular diagnostics overall sales rose growth underlying molecular business also sales sequencing business reporting decrease mainly us market growth molecular business sales came mainly biochemical reagents molecular diagnostics instruments human papillomavirus hpv screening regional growth led asiapacific notably china emea molecular diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales tissue diagnostics sales rose driven growth advanced staining portfolio growth companion diagnostics growth primary staining business regionally sales asiapacific grew china main growth factor tissue diagnostics regional sales change sales sales chf chf cer europe middle east africa emea north america rest world total sales roche finance report financial review roche group diagnostics division sales region change sales sales chf chf cer europe middle east africa emea north america asiapacific latin america japan total sales emea region divisions largest market main driver sales increase centralised point care solutions north america sales stable sales growth tissue diagnostics centralised point care solutions fully offset lower sales diabetes care business fell due continued price pressure sales increase asiapacific mainly china grew latin america sales rose due new tender business local inflationary price increases sales growth japan led centralised point care solutions business diagnostics division sales e leading emerging markets change sales sales chf chf cer brazil china india mexico russia south korea turkey total sales operating results diagnostics division royalties operating income change chf chf cer royalty income income outlicensing agreements income disposal products total ifrs core basis increase cer due increased royalty income mainly patent disputes combined additional income new licence agreements diagnostics division cost sales change chf chf cer manufacturing cost goods sold period costs royalty expenses cost sales core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer driven part unfavourable product mix higher instrument placements notably asiapacific region remainder increase arose higher depreciation placed instruments core cost sales ratio increased impairment charges relate partial impairment sequencing business intangible assets acquired part ariosa acquisition global restructuring costs mainly related site closures costs initiative harmonise processes systems roche finance report roche group financial review diagnostics division marketing distribution change chf chf cer marketing distribution core basis global restructuring plans amortisation intangible assets total ifrs basis core costs increased cer primarily due increased spending emerging markets asiapacific region especially china emea region core basis marketing distribution costs percentage sales stable global restructuring costs mainly due organisational changes divisional strategy plans diagnostics division research development change chf chf cer research development core basis global restructuring plans amortisation intangible assets impairment intangible assets total ifrs basis core costs increased cer increased spending integrated core laboratory digitalised data management projects partially offset decreased spending diabetes care molecular diagnostics blood screening hpv percentage sales research development core costs decreased impairment charges relate partial impairment molecular diagnostics intangible assets acquired part geneweave acquisition diagnostics division general administration change chf chf cer administration pensions past service costs gains losses disposal property plant equipment business taxes capital taxes general items general administration core basis global restructuring plans impairment goodwill intangible assets alliances business combinations legal environmental cases pensions settlement gains losses total ifrs basis core costs increased cer compared due base effect income changes groups swiss pension plans excluding effect core general administration costs increased administration costs increased due costs additional headcount notably china creation new legal entities diabetes care business business taxes included income settlement agreement medical devices excise tax us general items included income underspending infrastructure areas percentage sales core costs increased impairment relates goodwill sequencing business legal expenses mainly arose increasing litigation costs sequencing business roche finance report financial review roche group financial position diagnostics division net operating assets movement movement change change transactions cta chf chf chf cer chf chf trade receivables inventories trade payables net trade working capital receivablespayables net working capital property plant equipment goodwill intangible assets provisions longterm assets net longterm net operating assets net operating assets absolute amount movement consolidated balances reported swiss francs split actual transactions translated average rates currency translation adjustment cta arises consolidation transactions include noncash movements therefore movements table amounts shown operating free cash flow include cash movements full consolidated balance sheet given annual financial statements reconciliation balance sheet information given currency translation effects balance sheet amounts compared start year swiss franc depreciated significantly euro resulting positive translation impact net operating assets mostly offset appreciation swiss franc us dollar exchange rates used given net working capital net trade working capital increased cer trade receivables increased driven sales increase inventories decreased due inventories optimisation initiatives high demand trade payables decreased due lower spending net liability receivablespayables increased due higher liabilities sales rebates longterm net operating assets longterm net operating assets decreased cer due lower goodwill intangible assets partially offset higher property plant equipment lower provisions decrease goodwill intangible assets due impairments sequencing business molecular diagnostics property plant equipment increased due higher instrument placements manufacturing site expansion china germany provisions decreased following payment milestones related recent acquisitions roche finance report roche group financial review free cash flow diagnostics division operating free cash flow change change chf chf chf cer operating profit depreciation amortisation impairment provisions equity compensation plans operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow sales definition free cash flow detailed breakdown see pages operating free cash flow diagnostics division net cash inflow chf million compared chf million cash generation business measured operating profit net operating cash adjustments increased line sales growth buildup net working capital notably inventories repeated contributed yearonyear growth operating free cash flow capital expenditure chf billion major items described financial position section capital expenditure lower included significant site expansions roche finance report financial review roche group corporate operating results corporate operating results summary change chf chf cer administration pensions past service costs business taxes capital taxes general items general administration costs core basis global restructuring plans alliances business combinations legal environmental cases total costs ifrs basis financial position net working capital longterm net operating assets net operating assets free cash flow operating free cash flow see pages definition core results see pages definition free cash flow detailed breakdown general administration costs increased cer core basis driven base effect income pension changes excluding core costs higher due impairment corporate assets increased personnel related costs corporate project activities total costs ifrs basis increased included restructuring expenses offset legal environmental costs change net operating assets due utilisation provisions ongoing environmental remediation activities nutley us grenzach germany also due impairment assets corporate operating free cash flow showed higher outflow broadly line growth core costs excluding impact pension plans changes roche finance report roche group financial review foreign exchange impact operating results groups exposure movements foreign currencies affecting operating results expressed swiss francs summarised following key figures comments growth reported cer chf change cer change chf pharmaceuticals division sales core operating profit diagnostics division sales core operating profit group sales core operating profit exchange rates swiss franc december average december average usd eur jpy compared swiss franc weaker euro european currencies several major currencies asiapacific region partially offset swiss franc stronger japanese yen swiss franc remained stable us dollar net impact negligible results expressed swiss francs compared constant exchange rates sales core operating profit core eps sensitivity group sales core operating profit change average foreign currency exchange rates swiss franc shown table currency sensitivities impact increase average exchange rate sales core operating profit versus swiss franc chf chf us dollar euro japanese yen currencies groups revenues primarily generated sales products customers revenues mainly received local currency customers home market although certain emerging markets invoicing made major international currencies us dollar euro costs sales marketing also administration costs follow currency pattern sales majority research development activities incurred groups global research facilities therefore costs mainly concentrated us dollars swiss francs euros general administration costs tend incurred mainly central locations us switzerland germany chugais revenues costs denominated japanese yen roche finance report financial review roche group treasury taxation results treasury taxation results change change chf chf chf cer ifrs results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests financial position net debt pensions income taxes financial noncurrent assets derivatives net collateral net interest payable nonoperating assets net total net assets liabilities free cash flow treasury activities taxes paid total see pages definition core results see pages definition free cash flow financing costs core financing costs chf million decrease cer compared interest expenses including amortisation debt discount issue costs decreased chf million chf million due continued repayment refinancing debt lower interest rates losses bond redemptions chf million compared chf million net interest cost defined benefit pension plans decreased cer chf million mainly due lower discount rates germany end full analysis financing costs given note annual financial statements details debt repayments redemptions given note roche finance report roche group financial review financial income expense core financial income expense net income chf million compared net income chf million due lower foreign exchange losses higher net income equity securities net foreign exchange results reflect hedging costs losses unhedged positions net loss chf million compared net loss chf million core net income equity securities chf million compared chf million full analysis financial income expense given note annual financial statements income taxes groups effective core tax rate decreased percentage points largely due mix effects within manufacturing supply chain ifrs results show increase effective tax rate percentage points mainly due transitional effect changes us tax rates described noncore results including significant goodwill impairments tax deductible ifrs results also include noncore income releases contingent consideration provisions taxable hence net tax effect alliances business combinations line table changes us tax rates enacted december become effective january among changes decrease us federal tax rate group carried remeasurement deferred tax positions consequence net deferred tax asset recorded balance sheet reduced chf million end resulted transitional expense chf million treated noncore item remaining adjustments chf million recorded comprehensive income far relate temporary differences arising items recorded comprehensive income actuarial gainslosses us pension plans new rates applied whole excluding transition impacts groups effective core tax rate percentage terms would low twenties details groups income tax expenses related balance sheet positions given note annual financial statements analysis groups effective tax rate profit income profit income tax taxes tax rate tax taxes tax rate chf chf chf chf groups effective tax rate core basis global restructuring plans goodwill intangible assets alliances business combinations legal environmental cases transitional effect changes us tax rates normalisation equity compensation plan tax benefit groups effective tax rate ifrs basis financial position decrease net debt due free cash flow chf billion partly offset dividend payments chf billion net pension liability decreased due improved asset performance net tax liabilities decreased mainly due deferred tax impact impairment intangible assets partially offset deferred tax impact changes us tax rates announced late december group held financial longterm assets market value chf billion consist mostly holdings biotechnology pharmaceuticals companies acquired part licensing transactions scientific collaborations compared start year swiss franc appreciated us dollar positive translation impact groups net debt due us dollardenominated debt translating lower swiss franc amount yearend roche finance report financial review roche group free cash flow cash outflow treasury activities decreased chf billion due lower pension contributions lower interest payments well base effect investments financial longterm assets total taxes paid chf billion due higher tax payments us cash flows net debt operating free cash flow billions chf free cash flow billions chf free cash flow millions chf pharmaceuticals diagnostics corporate group operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid free cash flow operating profit ifrs basis operating profit cash adjustments operating profit net operating cash adjustments increase decrease net working capital investments property plant equipment investments intangible assets operating free cash flow treasury activities taxes paid free cash flow definition free cash flow detailed breakdown see pages operating free cash flow increased chf billion cer chf billion major factor significant increase growth underlying cash generated operations increased chf billion lower net working capital also contributed overall operating free cash flow compared increase net working capital especially impacted yearonyear growth rate addition capital expenditure lower cash outflow treasury activities went chf billion due lower pension contributions lower interest payments well base effect higher investments financial longterm assets taxes paid higher chf billion due higher us tax payments free cash flow chf billion significantly higher due higher operating free cash flow lower net cash outflow treasury operations roche finance report roche group financial review net debt millions chf january cash cash equivalents marketable securities longterm debt shortterm debt net debt beginning period change net debt free cash flow dividend payments transactions equity instruments business combinations net divestments subsidiaries hedging collateral arrangements currency translation fair value movements change net debt december cash cash equivalents marketable securities longterm debt shortterm debt net debt end period definition net debt see net debt currency profile millions chf cash marketable securities debt us dollar euro swiss franc japanese yen pound sterling total us dollardenominated debt includes bonds notes denominated euros swapped us dollars therefore consolidated results economic characteristics equivalent us dollardenominated bonds notes net debt position group december chf billion decrease chf billion december decrease due strong free cash flow partly offset dividend payments chf billion issuance redemption repurchase bonds notes see note annual financial statements impact liquid funds impact net debt position roche finance report financial review roche group contractual obligations commitments group obligations commitments set table carrying values shown consolidated balance sheet potential obligations shown discounted riskadjusted amounts denominated foreign currencies translated swiss francs december exchange rates contractual obligations commitments december millions chf potential obligation undiscounted less carrying year years years years total value onbalance sheet debt bonds notes debt contingent consideration provisions accounts payable derivative financial instruments unfunded defined benefit plans total onbalance sheet commitments offbalance sheet capital commitments property plant equipment operating leases contract manufacturing commitments alliance collaboration commitments total offbalance sheet commitments total contractual commitments references notes annual financial statements debt consists mainly bonds notes includes principal interest groups debt instruments debt mainly commercial paper carrying values discounted based interest rates inherent instruments contingent consideration provisions potential payments arising business combinations carrying values risk adjusted discounted unfunded defined benefit plans mainly pension plans groups german affiliates fully reserved pension obligations invested local affiliates operations carrying values discounted future company contributions groups funded plans shown table capital commitments property plant equipment noncancellable commitments purchase construction mainly roche sites basel switzerland mannheim germany south san francisco us also chugai sites operating leases future obligations noncancellable lease contracts group implement ifrs leases point obligations reported balance sheet contract manufacturing commitments future minimum takeorpay commitments purchase inventories arising groups major longterm agreements external contract manufacturing organisations cmos alliance collaboration commitments potential upfront milestone payments may become due groups inlicensing arrangements potential payments alliance partners asset deals within next three years included assuming projects currently development successful potential payments beyond three years included asset deals provisions legal environmental matters included table timing amount cash outflow uncertain contingent development matters question roche finance report roche group financial review pensions postemployment benefits postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions expenses groups defined contribution plans chf million chf million plans classified defined benefit plans even groups potential obligation minor relatively remote possibility arising plans usually established trusts independent group funded payments group employees cases plan unfunded group pays pensions retired employees directly financial resources defined benefit plans operating income chf million recorded past service costs changes groups pension plans switzerland represents impact adjustment pension liability plan changes announced expenses groups defined benefit plans chf million excluding past service costs chf million based revised actuarial assumptions end expenses groups defined benefit plans expected approximately chf million line estimates pension expenses include settlement past servicecurtailment effects might arise year funding status balance sheet position chf chf funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability overall funding status ifrs basis groups funded defined benefit plans increased compared start year plan assets increased chf billion driven higher returns assets partially offset items including settlement payments made us ireland funded status pension funds monitored local pension fund governance bodies well closely reviewed group level additional contributions paid groups pension plans us uk total cash outflow groups defined benefit plans chf million compared chf million included additional contributions paid groups pension plans switzerland us ireland year unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations unfunded liabilities plans increased chf million mainly due currency translation effect increase euro swiss franc year full details groups pensions postemployment benefits given note annual financial statements roche finance report financial review roche group roche shares share price market capitalisation december change chf share price chf nonvoting equity security genussschein price chf market capitalisation billions chf roche ranked number among peer group consisting roche healthcare companies total shareholder return tsr defined share price growth plus dividends measured swiss francs actual exchange rates constant exchange rates cer roche ranked number yearend return roche shares roche nonvoting equity securities combined performance share nonvoting equity security compared weighted average return peer group chf terms cer healthcare sector experienced positive performance together world markets driven recovery global economy normalisation monetary policy us eu gradual expected swiss market index smi posted gains however performance mixed relative major global indices currency movements continued influence investors exposure swiss equities smi underperforming major us indices outperforming european indices context even positive readouts end roche share performance continues impacted investor concern biosimilar impact competition cancer immunotherapy peer group abbott abbvie amgen astellas astrazeneca bayer bristolmyers squibb glaxosmithkline johnson johnson lilly merck co novartis pfizer roche sanofi takeda total shareholder return development dec mar june sept dec roche share roche nonvoting equity security peer set index source datastream data roche peer index rebased january peer index converted swiss francs daily actual exchange rates currency fluctuations influence representation relative performance roche versus peer index roche finance report roche group financial review proposed dividend board directors proposing increase dividend chf per share nonvoting equity security chf approval annual general meeting st consecutive increase dividend dividend proposal approved shareholders dividend payments total shares nonvoting equity securities amount chf billion chf billion resulting payout ratio based core net income based prices yearend dividend yield roche share yield nonvoting equity security information roche securities given pages information per share nonvoting equity security change chf chf chf eps basic eps diluted core eps basic core eps diluted equity attributable roche shareholders per share dividend per share details please refer notes annual financial statements payout ratio calculated dividend per share divided core earnings per share roche finance report financial review roche group debt debt redemptions following redemptions due date march chf million bonds due date september usd million bonds november group completed tender offer repurchase eur million notes due march gbp million notes due august debt issuances following issuances march group issued chf million bonds due september chf million bonds due september chf million bonds due march transactions described note annual financial statements maturity schedule groups bonds notes outstanding december shown table bonds notes nominal amounts december contractual maturity us dollar euro pound sterling swiss franc total total usd eur gbp chf usd chf beyond total total translated december exchange rates proceeds bonds notes eur million swapped us dollars therefore consolidated results bonds notes economic characteristics equivalent us dollardenominated bonds notes group plans meet debt obligations using existing liquid funds well cash generated business operations free cash flow chf billion included cash generated operations well payment interest tax shortterm financing requirements group commercial paper programme us issue usd billion unsecured commercial paper notes committed credit lines usd billion available backstop lines commercial paper notes totalling usd billion outstanding december usd billion longerterm financing group maintains strong longterm investmentgrade credit ratings aa standard poors moodys facilitate efficient access international capital markets information groups debt given note annual financial statements credit ratings roche group december shortterm longterm outlook moodys p stable standard poors aa stable roche finance report roche group financial review financial risks december group net debt position chf billion chf billion financial assets group managed conservative way objective meet groups financial obligations times asset allocation considerable portion cash marketable securities group currently holds used debt redemptions liquid funds either held cash invested highquality investmentgrade fixed income securities investment horizon meet liquidity requirements cash marketable securities chf total chf total cash cash equivalents money market instruments debt securities equity securities total cash marketable securities credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group rating profile groups chf billion cash fixed income marketable securities remained strong invested aaaa range group signed netting collateral agreements counterparties order mitigate counterparty risk derivative positions group trade receivables chf billion since beginning financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries december trade receivables eur billion chf billion public customers countries increase compared december euro terms due substantial collections late prior year end group uses different measures improve collections countries including intense communication customers factoring negotiations payment plans charging interest late payments legal actions since groups trade receivables balance southern europe decreased euro terms liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time addition current liquidity position group good cash generation ability future cash flows used repay debt instruments coming years roche enjoys strong longterm investmentgrade credit ratings aa standard poors moodys time roche rated highest available shortterm ratings agencies event financing requirements ratings overall creditworthiness roche group permit efficient access international capital markets including commercial paper market group committed credit lines various financial institutions totalling usd billion available backstop lines commercial paper programme december debt drawn credit lines market risk market risk arises changing market prices groups financial assets financial liabilities exposures predominantly related changes interest rates foreign exchange rates equity prices group uses valueatrisk var assess impact market risk financial instruments var data indicates value range within given financial instrument fluctuate preset probability result movements market prices groups var remained stable interest rate risk interest rate risk arises movements interest rates could affect group financial result value group equity group may use interest rate derivatives manage interestraterelated exposure financial result information financial risk management financial risks var methodology included note annual financial statements roche finance report financial review roche group international financial reporting standards roche group using international financial reporting standards ifrs report consolidated results since group implemented various minor amendments existing standards interpretations material impact groups overall results financial position new revised standards applied group assessed expected impacts various new revised standards interpretations mandatory january group yet applied summarised group anticipate material impact groups overall results financial position furthermore restatements comparative results necessary new standards applied see note annual financial statements details ifrs financial instruments group implement new standard effective january apply exemption full retrospective application classification measurement requirements including impairment meaning comparative results restated new standard applied standard deals classification recognition measurement including impairment financial instruments impairment financial assets including trade lease receivables also introduces new hedge accounting model ifrs revenues contracts customers group implement new standard effective january apply full retrospective method transition since new standard change amounts revenue recognised restatements comparative results necessary new standard contains new set principles recognise measure revenue well new requirements related presentation core principle framework revenue recognised dependent transfer promised goods services customer amount reflects consideration received exchange goods services new revised standards applied beyond ifrs leases group implement new standard effective january apply cumulative catchup method option transition meaning comparative results restated new standard applied main impact new standard bring operating leases onbalance sheet group assessing potential impact currently anticipates new standard result carrying value leased assets increased approximately chf billion lease liabilities increased similar amount date implementation application new standard result part currently reported operating lease costs recorded interest expenses given leases involved prevailing low interest rate environment group currently expect effect material see note annual financial statements details matters roche finance report roche group roche group consolidated financial statements roche group consolidated financial statements roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group consolidated financial statements roche group roche group consolidated income statement year ended december millions chf pharmaceuticals diagnostics corporate group sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests earnings per share nonvoting equity security basic chf diluted chf roche finance report roche group roche group consolidated financial statements roche group consolidated statement comprehensive income millions chf year ended december net income recognised income statement comprehensive income remeasurements defined benefit plans items never reclassified income statement availableforsale investments cash flow hedges currency translation foreign operations items may reclassified income statement comprehensive income net tax total comprehensive income attributable roche shareholders noncontrolling interests total roche finance report roche group consolidated financial statements roche group roche group consolidated balance sheet millions chf december december december noncurrent assets property plant equipment goodwill intangible assets deferred tax assets defined benefit plan assets noncurrent assets total noncurrent assets current assets inventories accounts receivable current income tax assets current assets marketable securities cash cash equivalents total current assets total assets noncurrent liabilities longterm debt deferred tax liabilities defined benefit plan liabilities provisions noncurrent liabilities total noncurrent liabilities current liabilities shortterm debt current income tax liabilities provisions accounts payable current liabilities total current liabilities total liabilities total net assets equity capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity roche finance report roche group roche group consolidated financial statements roche group consolidated statement cash flows millions chf year ended december cash flows operating activities cash generated operations increase decrease net working capital payments made defined benefit plans utilisation provisions disposal products operating cash flows cash flows operating activities income taxes paid income taxes paid total cash flows operating activities cash flows investing activities purchase property plant equipment purchase intangible assets disposal property plant equipment disposal intangible assets business combinations divestment subsidiaries interest dividends received sales equity securities debt securities purchases equity securities debt securities sales purchases money market instruments time accounts three months net investing cash flows total cash flows investing activities cash flows financing activities proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt hedging collateral arrangements changes noncontrolling interests equity contribution noncontrolling interests interest paid dividends paid equitysettled equity compensation plans net transactions equity financing cash flows total cash flows financing activities net effect currency translation cash cash equivalents increase decrease cash cash equivalents cash cash equivalents january cash cash equivalents december group expanded presentation investing cash flows relating marketable securities sales purchases money market instruments time accounts three months shown separately net basis comparative period information restated accordingly roche finance report roche group consolidated financial statements roche group roche group consolidated statement changes equity millions chf non share retained fair value hedging translation controlling total capital earnings reserves reserves reserves total interests equity year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december year ended december january net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december roche finance report roche group notes roche group consolidated financial statements notes roche group consolidated financial statements general accounting principles basis preparation consolidated financial statements hereafter annual financial statements roche group prepared accordance international financial reporting standards ifrs comply swiss law prepared using historical cost convention except items required accounted fair value approved issue board directors january subject approval annual general meeting shareholders march financial statements annual financial statements roche holding ltd company registered switzerland subsidiaries group groups significant accounting policies changes accounting policies disclosed note key accounting judgements estimates assumptions preparation annual financial statements requires management make judgements estimates assumptions affect reported amounts revenues expenses assets liabilities contingent amounts actual outcomes could differ management estimates estimates underlying assumptions reviewed ongoing basis based historical experience various factors revisions estimates recognised period estimate revised following considered key accounting judgements estimates assumptions made believed appropriate based upon currently available information revenue nature groups business many sales transactions simple structure may consist multiple components occurring different times group also party outlicensing agreements involve upfront milestone payments occurring several years may also involve certain future obligations revenue recognised managements judgement significant risks rewards ownership transferred group retain continuing managerial involvement effective control goods sold obligation fulfilled transactions result cash receipts initially recognised deferred income released income subsequent periods basis performance conditions specified agreement may circumstances level sales returns hence revenues reliably measured cases sales recognised right return expires generally upon prescription products patients order estimate management uses publicly available information prescriptions well information provided wholesalers intermediaries revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales december group chf million provisions accruals expected sales returns chargebacks rebates including medicaid us similar rebates countries provisions accruals relating us pharmaceuticals business amounted chf million chf million related expected sales returns estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted could effect sales earnings period adjustment december group chf million provisions doubtful receivables see note estimates based analyses ageing customer balances specific credit circumstances historical trends groups experience taking also account current economic conditions business combinations group initially recognises fair value identifiable assets acquired liabilities assumed non controlling interest consideration transferred business combination management judgement particularly involved recognition fair value measurement intellectual property inventories contingent liabilities contingent consideration making assessment management considers underlying economic substance items concerned addition contractual terms roche finance report notes roche group consolidated financial statements roche group impairment december group chf million property plant equipment see note chf million goodwill see note chf million intangible assets see note goodwill intangible assets yet available use reviewed annually impairment property plant equipment intangible assets use assessed impairment triggering event provides evidence asset may impaired assess whether impairment exists estimates expected future cash flows used actual outcomes could vary significantly estimates factors changes discount rates planned use buildings machinery equipment closure facilities presence competition technical obsolescence lowerthananticipated product sales could lead shorter useful lives impairment pensions postemployment benefits group operates number defined benefit plans fair values recognised plan assets liabilities based upon statistical actuarial calculations measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions december present value groups defined benefit obligation chf million see note actuarial assumptions used may differ materially actual results due changes market economic conditions longer shorter life spans participants changes factors assessed differences could impact defined benefit plan assets liabilities recognised balance sheet future periods legal provisions group provides anticipated legal settlement costs probable outflow resources reliably estimated december group chf million legal provisions status significant legal cases disclosed note estimates consider specific circumstances legal case relevant legal advice inherently judgemental due highly complex nature legal cases estimates could change substantially time new facts emerge legal case progresses reliable estimate made provision recorded contingent liabilities disclosed material environmental provisions group provides anticipated environmental remediation costs probable outflow resources reasonably estimated december group chf million environmental provisions see note environmental provisions consist primarily costs fully clean refurbish contaminated sites including landfills treat contain contamination certain sites estimates inherently judgemental due uncertainties related detection previously unknown contamination method extent remediation percentage problematic materials attributable group remediation sites financial capabilities potentially responsible parties estimates could change substantially time new facts emerge environmental remediation progresses contingent consideration provisions group makes provision estimated fair value contingent consideration arrangements arising business combinations december group chf million contingent consideration provisions see note total potential payments contingent consideration arrangements business combinations could chf million see note estimated amounts provided expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario discounted net present value estimates could change substantially time new facts emerge scenario develops income taxes december group current income tax net liability chf million deferred tax net asset chf million see note significant estimates required determine current deferred tax assets liabilities estimates based interpretations existing tax laws regulations tax positions uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience factors may impact current deferred taxes include changes tax laws regulations rates changing interpretations existing tax laws regulations future levels research development spending changes pretax earnings leases treatment leasing transactions mainly determined whether lease considered operating finance lease making assessment management looks substance lease well legal form makes judgement whether substantially risks rewards ownership transferred arrangements take legal form lease nevertheless convey right use asset also covered assessments consolidation group periodically undertakes transactions may involve obtaining control significant influence companies transactions include equity acquisitions asset purchases alliance agreements cases management makes assessment whether group control significant influence company whether consolidated subsidiary accounted associated company making assessment management considers underlying economic substance transaction addition contractual terms roche finance report roche group notes roche group consolidated financial statements operating segment information group two divisions pharmaceuticals diagnostics revenues primarily generated sale prescription pharmaceutical products diagnostic instruments reagents consumables respectively divisions also derive revenues sale licensing products technology third parties residual operating activities divested businesses certain global activities reported corporate include corporate executive committee global group functions communications human resources finance including treasury taxes pension fund management legal safety environmental services subdivisional information roche pharmaceuticals chugai operating segments within pharmaceuticals division also presented divisional information millions chf pharmaceuticals diagnostics corporate group revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination interdivisional revenue total segment results operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total research development research development costs segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets inventory fair value adjustment equity compensation plan expenses roche finance report notes roche group consolidated financial statements roche group pharmaceuticals subdivisional information millions chf roche pharmaceuticals chugai pharmaceuticals division revenues external customers sales royalties operating income total revenues operating segments sales royalties operating income elimination income within division total segment results operating profit elimination results within division operating profit capital expenditure business combinations additions property plant equipment additions intangible assets total research development research development costs elimination costs within division total segment information depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets inventory fair value adjustment equity compensation plan expenses net operating assets millions chf assets liabilities net assets pharmaceuticals diagnostics corporate total operating nonoperating group roche finance report roche group notes roche group consolidated financial statements net operating assets pharmaceuticals subdivisional information millions chf assets liabilities net assets roche pharmaceuticals chugai elimination within division pharmaceuticals division information geographical area millions chf revenues external customers noncurrent assets royalties property plant goodwill sales operating income equipment intangible assets switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total supplementary unaudited information sales therapeutic areas pharmaceuticals division business areas diagnostics division given financial review sales allocated geographical areas destination according location customer royalties operating income allocated according location group company receives revenue roche finance report notes roche group consolidated financial statements roche group major customers total three us national wholesale distributors represent approximately third groups revenues three us national wholesale distributors mckesson corp chf billion chf billion amerisourcebergen corp chf billion chf billion cardinal health inc chf billion chf billion approximately revenues pharmaceuticals operating segment residual diagnostics segment supplementary revenues information revenues product sales recorded net allowances estimated rebates chargebacks cash discounts estimates product returns established time sale product sales allowances based estimates amounts earned claimed related sales estimates take consideration historical experience current contractual statutory requirements specific known market events trends competitive pricing new product introductions estimated inventory levels shelf life products actual future results vary estimates need adjusted could effect sales earnings period adjustment grosstonet sales reconciliation pharmaceuticals division shown table companies diagnostics division similar reconciling items much lower amounts pharmaceuticals division sales grosstonet reconciliation millions chf gross sales government regulatory mandatory price reductions contractual price reductions cash discounts customer returns reserves others net sales government regulatory mandatory price reductions consist mandatory price reductions major elements b drug discount program medicaid plans us totalled usd billion equivalent chf billion usd billion equivalent chf billion contractual price reductions include rebates chargebacks result contractual agreements primarily volumebased performancebased cash discounts include credits offered wholesalers remitting payment purchases within contractually defined incentive periods customer returns reserves allowances established expected product returns sales reductions expected withheld customer upon settlement contractual price reductions cash discounts recorded balance sheet deduction trade receivables see note sales reductions separately payable customers governmental health authorities healthcare regulatory authorities recorded balance sheet accrued liabilities see note provisions sales returns recorded balance sheet provisions see note revenues royalties operating income millions chf royalty income income outlicensing agreements income disposal products total royalty operating income roche finance report roche group notes roche group consolidated financial statements income outlicensing agreements included upfront payment exclusive licence agreement dermira development worldwide commercialisation lebrikizumab atopic dermatitis potential indications income disposal products included divestment worldwide rights bonviva bondronat excluding us japan dilatrend kytril excluding japan income product disposals operating income included product divestment xenical net financial expense financing costs millions chf interest expense amortisation debt discount net gains losses debt derivatives net gains losses redemption repurchase bonds notes discount unwind net interest cost defined benefit plans total financing costs financial income expense millions chf net gains losses sale equity securities net gains losses equity security derivatives dividend income writedowns impairments equity securities net income equity securities interest income net gains losses sale debt securities net interest income income debt securities net foreign exchange gains losses net gains losses foreign currency derivatives foreign exchange gains losses net financial income expense associates total financial income expense roche finance report notes roche group consolidated financial statements roche group net financial expense millions chf financing costs financial income expense net financial expense financial result treasury management financial result pension management associates net financial expense income taxes income tax expenses millions chf current income taxes deferred taxes total income tax expense since group operates internationally subject income taxes many different tax jurisdictions group calculates average expected tax rate weighted average tax rates tax jurisdictions group operates rate changes year year due changes mix groups taxable income changes local tax rates groups average expected tax rate decreased decrease mainly due lower proportion groups profits us relatively higher local tax rate groups average tax rate lower proportion us profits driven goodwill impairments groups effective tax rate increased main drivers increase goodwill impairments mentioned tax deductible impact intragroup transfer intangible rights transitional effect changes us tax rates december changes us tax rates enacted become effective january among changes decrease us federal tax rate group carried remeasurement deferred tax positions consequence net deferred tax asset recorded balance sheet reduced chf million end resulted transitional expense chf million remaining adjustments chf million recorded comprehensive income far relate temporary differences arising items recorded comprehensive income actuarial gainslosses us pension plans roche finance report roche group notes roche group consolidated financial statements groups effective tax rate reconciled groups average expected tax rate follows reconciliation groups effective tax rate average expected tax rate tax effect nontaxable incomenondeductible expenses equity compensation plans research development tax credits manufacturing deductions us state tax impacts tax unremitted earnings utilisation previously unrecognised tax losses deferred tax intragroup transfers transitional effect changes us tax rates prior year differences groups effective tax rate income tax benefit recorded respect equity compensation plans varies according price underlying equity chf million chf million income tax benefits recorded solely basis ifrs expense multiplied applicable tax rate benefit approximately chf million chf million would recorded tax effects comprehensive income millions chf pretax aftertax pretax aftertax amount tax amount amount tax amount remeasurements defined benefit plans availableforsale investments cash flow hedges currency translation foreign operations comprehensive income income tax assets liabilities millions chf current income taxes assets liabilities net current income tax assets liabilities deferred taxes assets liabilities net deferred tax assets liabilities current income tax liabilities include accruals uncertain tax positions roche finance report notes roche group consolidated financial statements roche group current income taxes movements recognised net assets liabilities millions chf net current income tax asset liability january income taxes paid business combinations charged credited income statement charged credited equity equity compensation plans transactions shareholders currency translation effects movements net current income tax asset liability december deferred taxes movements recognised net assets liabilities millions chf property defined plant intangible benefit temporary equipment assets plans differences total year ended december january charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december year ended december january business combinations charged credited income statement charged credited comprehensive income charged credited equity equity compensation plans transactions shareholders currency translation effects movements december deferred tax net assets temporary differences mainly relate accrued liabilities provisions unrealised profit inventory deferred tax assets recognised tax losses carried forward extent realisation related tax benefit probable group unrecognised tax losses including valuation allowances follows unrecognised tax losses expiry amount applicable amount applicable chf tax rate chf tax rate within one year one five years five years total unrecognised tax losses five years category includes losses used us state income tax purposes states permit tax reporting separate entity basis deferred tax liabilities established withholding tax taxes would payable remittance earnings foreign subsidiaries amounts currently regarded permanently reinvested purpose financial statements total unremitted earnings group regarded permanently reinvested purpose financial statements chf billion december chf billion roche finance report roche group notes roche group consolidated financial statements business combinations acquisitions mysugr gmbh june group acquired controlling interest mysugr gmbh mysugr private company based vienna austria mysugr developed one leading mobile diabetes platforms market become part groups new digital health services diabetes care acquisition mysugr expands groups leading position area diabetes management mysugr reported diagnostics operating segment part diabetes care business total cash consideration eur million viewics inc november group acquired controlling interest viewics inc viewics us privately owned company based san jose california viewics software company focused laboratory business analytics solution acquisition viewics expands groups leading position integrated core lab business analytics capabilities enabling laboratories make faster datadriven informed decisions operations processes viewics reported diagnostics operating segment total consideration usd million usd million paid cash usd million deferred consideration paid period date control usd million arose contingent consideration arrangement contingent payments based achievement performancerelated milestones range undiscounted outcomes zero usd million identifiable assets acquired liabilities assumed set table amounts mysugr viewics provisional based preliminary information valuations assets liabilities subject adjustment acquisitions net assets acquired millions chf mysugr viewics total intangible assets product intangibles use product intangibles available use marketing intangibles use cash cash equivalents deferred tax liabilities net assets liabilities net identifiable assets fair value previously held interest goodwill total consideration cash deferred consideration contingent consideration total consideration fair value product intangible asset mysugr determined using replacement cost method fair value intangible assets determined using excess earning method based management forecasts observable market data discount rates tax rates foreign exchange rates present value calculated using riskadjusted discount rate mysugr viewics valuations performed independent valuers viewics accounts receivable comprised gross contractual amounts due chf million expected collectable date acquisition goodwill represents control premium acquired work force synergies expected integrating acquired companies groups existing business none goodwill expected deductible income tax purposes roche finance report notes roche group consolidated financial statements roche group group recognised financial gain chf million chf million respectively fair valuing interest mysugr interest viewics held group prior transaction gain included financial income expense directly attributable transaction costs chf million reported diagnostics operating segment within general administration expenses impact mysugr viewics acquisitions results diagnostics division group material future acquisitions ignyta inc december group announced entered merger agreement ignyta inc ignyta fully acquire ignyta price usd per share allcash transaction corresponds total transaction value usd billion fully diluted basis ignyta publicly owned us company based san diego california listed nasdaq stock code rxdx closing transaction expected take place first half subject majority ignytas outstanding shares tendered group expiration termination waiting period hartscottrodino antitrust improvements act customary conditions upon closing ignyta reported pharmaceuticals division acquisitions group complete business combinations cash flows business combinations acquisitions net cash outflow millions chf pharmaceuticals diagnostics total pharmaceuticals diagnostics total cash consideration paid deferred consideration paid contingent consideration paid cash acquired company transaction costs total net cash outflow roche finance report roche group notes roche group consolidated financial statements global restructuring plans group initiated various resourcing flexibility plans pharmaceuticals division address various future challenges including biosimilar competition areas plans include biologics manufacturing commercial operations product development strategy group also continued implementation several major global restructuring plans initiated prior years notably strategic realignment pharmaceuticals divisions manufacturing network programmes address longterm strategy diagnostics division global restructuring plans costs incurred millions chf diagnostics site consolidation plans total year ended december global restructuring costs employeerelated costs site closure costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs year ended december global restructuring costs employeerelated costs site closure costs reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs includes strategy plans diagnostics division diabetes care autonomy speed plan includes pharmaceuticals divisions strategic realignment manufacturing network resourcing flexibility biologics manufacturing network includes plans resourcing flexibility pharmaceuticals divisions commercial operations global product developmentstrategy organisations pharmaceuticals divisions research development strategic realignment outsourcing functions diagnostics division strategy plans diagnostics division launched incurred costs chf million mainly employee related costs chf million related site closures employees spending smaller plans within division chf million chf million included costs related autonomy speed initiative diabetes care certain projects roche finance report notes roche group consolidated financial statements roche group site consolidation november pharmaceuticals division announced strategic realignment manufacturing network including exiting manufacturing sites clarecastle ireland legans spain segrate italy florence us costs plan chf million chf million chf million noncash impairments accelerated depreciation property plant equipment chf million employeerelated provisions reversed likely scenario segrate site changed closure divestment divestment florence segrate legans sites completed result total costs chf million includes chf million accumulated currency translation losses consolidation transferred income statement see note expected costs environmental remediation clarecastle site reassessed resulted increase provisions environmental remediation see note plans include resourcing flexibility biologics manufacturing network resulted headcount reductions us also kaiseraugst site switzerland exit small molecules manufacturing site toluca mexico divestment nutley site us completed second half resulted increase provisions environmental remediation global restructuring plans total costs chf million major item chf million resourcing flexibility pharmaceuticals division including global field force reductions notably us europe remaining chf million includes plans outsourcing functions shared service centres external providers total costs chf million major items chf million pharmaceuticals division research development strategic realignment chf million informatics mainly outsourcing functions shared service centres external providers remaining minor plans totalled chf million global restructuring plans summary costs incurred millions chf employeerelated costs termination costs defined benefit plans employeerelated costs total employeerelated costs site closure costs impairment property plant equipment accelerated depreciation property plant equipment gains losses disposal property plant equipment site closure costs total site closure costs divestment products businesses gains losses divestment subsidiaries gains losses divestment products businesses total costs divestment products businesses reorganisation expenses total global restructuring costs additional costs impairment goodwill impairment intangible assets legal environmental cases total costs roche finance report roche group notes roche group consolidated financial statements global restructuring plans classification costs millions chf depreciation depreciation amortisation amortisation impairment costs total impairment costs total cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics general administration pharmaceuticals diagnostics corporate total total operating segment roche pharmaceuticals chugai diagnostics corporate total roche finance report notes roche group consolidated financial statements roche group property plant equipment property plant equipment movements carrying value assets millions chf buildings land machinery construction land improvements equipment progress total january cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value year ended december january business combinations additions disposals divestment subsidiaries transfers depreciation charge impairment charge currency translation effects december cost accumulated depreciation impairment net book value classification impairment property plant equipment millions chf cost sales marketing distribution research development general administration total impairment charge impairment charges property plant equipment mainly related global restructuring plans see note reimbursements received insurance companies respect impairments property plant equipment none borrowing costs capitalised property plant equipment none roche finance report roche group notes roche group consolidated financial statements divestment nutley site september group completed divestment nutley site total net consideration received cash chf million genentech property purchase option exercise genentech entered master lease agreement mla slough ssf llc slough subsequently acquired health care properties lease property adjacent genentechs south san francisco site developed slough development included total eight buildings construction completed time genentech fully occupied property property lease extension options november genentech exercised purchase option contained mla acquire eight buildings land december group recorded addition land buildings land improvements corresponding liabilities cash outflows group also reclassified finance lease accounting balances previously applied buildings november first closing payment usd million made final closing payment usd million due july recorded current liability see note leasing arrangements group lessee finance leases december capitalised cost property plant equipment finance leases chf million chf million net book value assets chf million chf million carrying value leasing obligation chf million chf million reported part debt see note finance leases future minimum lease payments noncancellable leases millions chf future minimum lease present value minimum lease payments payments within one year one five years five years total future finance charges total future minimum lease payments undiscounted operating leases group companies party number operating leases mainly property rentals motor vehicles arrangements impose significant restrictions group total operating lease rental expense chf million chf million operating leases future minimum lease payments noncancellable leases millions chf within one year one five years five years total minimum payments leasing arrangements group lessor finance leases certain assets mainly diagnostics instruments leased third parties finance lease arrangements assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method roche finance report notes roche group consolidated financial statements roche group finance leases future minimum lease receipts noncancellable leases millions chf present value minimum gross investment lease lease receipts within one year one five years five years total unearned finance income na na unguaranteed residual value na na net investment lease accumulated allowance uncollectible minimum lease payments chf million chf million operating leases certain assets mainly diagnostics instruments leased third parties operating lease arrangements assets reported within property plant equipment lease income operating leases recognised lease term straightline basis december machinery equipment original cost chf billion chf billion net book value chf billion chf billion leased third parties operating leases future minimum lease receipts noncancellable leases millions chf within one year one five years five years total minimum receipts capital commitments group noncancellable capital commitments purchase construction property plant equipment totalling chf billion chf billion roche finance report roche group notes roche group consolidated financial statements goodwill goodwill movements carrying value assets millions chf january cost accumulated impairment net book value year ended december january business combinations impairment charge currency translation effects december cost accumulated impairment net book value allocated following cashgenerating units roche pharmaceuticals foundation medicine chugai total pharmaceuticals division diabetes care centralised point care solutions molecular diagnostics tissue diagnostics sequencing divisional goodwill total diagnostics division impairment charge impairment charges totalling chf million related charge chf million diagnostics division full writeoff sequencing business goodwill factors leading impairment decrease forecasted cash flows relative previous years longterm forecast due changed assumptions around market penetration pricing reimbursement ii revised time market single molecule sequencing technology addition impairment charges chf million recorded sequencing business product intangibles use acquired part ariosa acquisition see note charge chf million pharmaceuticals division full writeoff goodwill relating seragon acquisition due decision stop development backup compound acquired impairment charge goodwill impairment charge chf million recorded pharmaceuticals division full writeoff goodwill anadys pharmaceuticals inc acquisition deemed disposed roche finance report notes roche group consolidated financial statements roche group impairment testing pharmaceuticals division divisions operating segments cashgenerating units used testing goodwill part goodwill arising foundation medicine acquisition recorded monitored roche pharmaceuticals level relates strategic development roche pharmaceuticals therefore cashgenerating unit strategic goodwill roche pharmaceuticals recoverable amount used impairment testing higher value use fair value less costs disposal chugai foundation medicine fair value less costs disposal determined reference publicly quoted share prices chugai foundation medicine shares diagnostics division divisions business areas cashgenerating units used testing goodwill goodwill arising corangeboehringer mannheim acquisition part goodwill ventana acquisition recorded monitored divisional level relates strategic development whole division meaningfully allocated divisions business areas therefore cashgenerating unit goodwill entire division goodwill arising viewics acquisition monitored divisional level recoverable amount used impairment testing based value use value use calculated using discounted expected cash flow approach posttax discount rate applied projected riskadjusted posttax cash flows terminal value discount rate groups weighted average cost capital cash generating units integrated operations across large parts group derived capital asset pricing model using data capital markets including government twentyyear bonds assessing value use cash flow projections based recent longterm forecasts approved management longterm forecasts include managements latest estimates sales volume pricing well production operating costs assume significant changes organisation key assumptions used calculations period cash flow projections included longterm forecasts terminal value growth rate discount rate key assumptions used value use calculations period terminal period terminal cash flow value discount rate cash flow value discount rate projections growth rate tax projections growth rate tax pharmaceuticals division roche pharmaceuticals years na years na diagnostics division sequencing years years diagnostics businesses years years cashgenerating units terminal value growth respective rate exceed longterm projected growth rate relevant market ten years period cash flow projections reflects longterm nature development sequencing business sensitivity analysis management performed sensitivity analyses roche pharmaceuticals diagnostics division increased discount rate combined decreasing forecast cash flows chugai foundation medicine decreased publicly quoted share prices results sensitivity analyses demonstrated changes key assumptions would cause carrying values goodwill exceed recoverable amounts december roche finance report roche group notes roche group consolidated financial statements intangible assets intangible assets movements carrying value assets millions chf product product intangibles marketing technology intangibles available intangibles intangibles use use use use total january cost accumulated amortisation impairment net book value year ended december january additions disposal transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group year ended december january business combinations additions disposal transfers amortisation charge impairment charge currency translation effects december cost accumulated amortisation impairment net book value allocated operating segment roche pharmaceuticals chugai diagnostics total group roche finance report notes roche group consolidated financial statements roche group significant intangible assets december millions chf remaining operating segment net book value amortisation period product intangibles use intermune acquisition roche pharmaceuticals years foundation medicine acquisition roche pharmaceuticals years ariosa acquisition diagnostics years kapa acquisition diagnostics years cmi acquisition diagnostics years iquum acquisition diagnostics years product intangibles available use biontech licence transaction roche pharmaceuticals na geneweave acquisition diagnostics na genia acquisition diagnostics na technology intangibles use dutalys acquisition roche pharmaceuticals years classification intangible asset amortisation impairment expenses millions chf amortisation impairment cost sales pharmaceuticals diagnostics marketing distribution pharmaceuticals diagnostics research development pharmaceuticals diagnostics total internally generated intangible assets group currently internally generated intangible assets development criteria recognition asset met intangible assets indefinite useful lives group currently intangible assets indefinite useful lives intangible assets available use mostly represent inprocess research development assets acquired either inlicensing arrangements business combinations separate purchases december approximately projects pharmaceuticals division known decision points within next twelve months certain circumstances could lead impairment due inherent uncertainties research development processes intangible assets available use particularly risk impairment project expected result commercialised product roche finance report roche group notes roche group consolidated financial statements intangible asset impairment impairment charges arise changes estimates future cash flows expected result use asset eventual disposal factors presence absence competition technical obsolescence lowerthananticipated sales products capitalised rights could result shortened useful lives impairment impairment charges pharmaceuticals division impairment charges totalling chf million recorded related charge chf million partial impairment esbriet product intangible use acquired part intermune acquisition asset concerned written estimated recoverable value chf million main factor leading decrease forecasted cash flows relative previous years longterm forecast due reduction sales expectations intangible asset continues amortised remaining estimated useful life four years charge chf million due launch competitor product compound acquired part trophos acquisition asset concerned yet amortised written estimated recoverable value chf million charge chf million due decision stop development one compound alliance partner following assessment clinical nonclinical data asset concerned yet amortised fully written charge chf million due decision stop development one compound acquired part dutalys acquisition asset concerned yet amortised fully written charge chf million due decision stop development one compound acquired part santaris acquisition following clinical data assessment asset concerned yet amortised fully written charge chf million due decision stop development two compounds two different alliance partners assets concerned yet amortised fully written charge chf million following clinical data assessments assets concerned yet amortised fully written diagnostics division impairment charges totalling chf million recorded related charge chf million partial impairment molecular diagnostics product intangibles available use acquired part geneweave acquisition factor leading partial impairment decrease forecasted cash flows following change timelines future product development pricing penetration rate due updated market size assumptions asset concerned yet amortised written estimated recoverable value chf million charge chf million partial impairment sequencing business product intangibles use acquired part ariosa acquisition factor leading impairment decrease forecasted cash flows following revised assumptions pricing penetration rate due market dynamics asset concerned amortised written estimated recoverable value chf million impairment charges pharmaceuticals division impairment charges totalling chf million recorded related decision stop development one compound acquired part seragon acquisition following clinical data assessment chf million asset concerned yet amortised fully written delay development compound acquired part trophos acquisition following regulatory feedback chf million asset concerned yet amortised written estimated recoverable value chf million portfolio reassessment one compound chf million asset concerned yet amortised fully written clinical data assessment two development projects two different alliance partners chf million assets concerned yet amortised fully written decision stop development three compounds chf million assets concerned yet amortised fully written diagnostics division impairment charges totalling chf million recorded related sequencing product intangibles use chf million result decision stop product development commercialisation licence agreement alliance partner asset concerned amortised fully written tissue diagnostics product intangibles use chf million result strategic portfolio reassessment asset concerned amortised fully written roche finance report notes roche group consolidated financial statements roche group potential commitments alliance collaborations purchase agreements within next three years group party inlicensing similar arrangements alliance partners intangible asset purchase agreements third parties arrangements purchase agreements may require group make certain milestone similar payments dependent upon achievement agreed objectives performance targets defined collaboration purchase agreements groups current estimate future thirdparty commitments payments within next three years set table figures undiscounted riskadjusted meaning include potential payments arise assuming projects currently development successful timing based groups current best estimate figures include potential commitments within group may arise roche chugai businesses potential future thirdparty collaboration purchase payments december millions chf pharmaceuticals diagnostics group within one year one two years two three years total inventories inventories millions chf raw materials supplies work process intermediates finished goods provision slowmoving obsolete inventory total inventories inventories expensed cost sales totalled chf billion chf billion inventory writedowns year resulted expense chf million chf million accounts receivable accounts receivable millions chf trade receivables notes receivable receivables allowances doubtful accounts chargebacks allowances withheld upon settlement total accounts receivable roche finance report roche group notes roche group consolidated financial statements allowances doubtful accounts movements recognised liability millions chf january additional allowances created unused amounts reversed utilised year currency translation effects december bad debt expenses recorded marketing distribution costs totalled chf million expense chf million marketable securities marketable securities millions chf availableforsale financial assets equity securities debt securities money market instruments time accounts three months investments total marketable securities marketable securities held fund management purposes primarily denominated swiss francs us dollars euros money market instruments contracted mature within one year december debt securities contracted maturity millions chf within one year one five years five years total debt securities cash cash equivalents cash cash equivalents millions chf cash cash hand current call accounts cash equivalents time accounts maturity three months less total cash cash equivalents roche finance report notes roche group consolidated financial statements roche group noncurrent assets noncurrent assets millions chf availableforsale investments held fair value availableforsale investments held cost loans receivable longterm trade receivables restricted cash receivables total financial noncurrent assets longterm employee benefits assets total nonfinancial noncurrent assets associates total noncurrent assets availableforsale investments mainly equity investments private biotechnology companies kept part groups strategic alliance efforts unquoted equity investments classified availableforsale measured cost fair value measured reliably current assets current assets millions chf accrued interest income derivative financial instruments restricted cash cash collateral receivables receivables total financial current assets prepaid expenses accrued income taxes recoverable assets total nonfinancial current assets total current assets receivables mainly related royalty licensing income receivables roche finance report roche group notes roche group consolidated financial statements accounts payable accounts payable millions chf trade payables taxes payable dividends payable payables total accounts payable noncurrent liabilities noncurrent liabilities millions chf deferred income longterm liabilities total noncurrent liabilities longterm liabilities mainly related accrued employee benefits included genentech property purchase option exercise obligation due july see note current liabilities current liabilities millions chf deferred income accrued payroll related items interest payable derivative financial instruments cash collateral payables accrued chargebacks allowances separately payable accrued royalties commissions accrued liabilities total current liabilities december accrued liabilities included chf million shortterm genentech property purchase option exercise obligation due july see note roche finance report notes roche group consolidated financial statements roche group provisions contingent liabilities provisions movements recognised liabilities millions chf contingent legal environmental restructuring consideration provisions provisions provisions provisions provisions total year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration currency translation effects december current noncurrent december year ended december january additional provisions created unused amounts reversed utilised discount unwind business combinations acquired companies deferred consideration contingent consideration currency translation effects december current noncurrent december expected outflow resources within one year one two years two three years three years december group revised presentation provisions contingent consideration provisions presented separately employee provisions included part provisions comparative period information restated accordingly chf million provisions utilised chf million chf million chf million included cash flows operating activities chf million chf million included cash flows business combinations payments made deferred contingent consideration arrangements see note roche finance report roche group notes roche group consolidated financial statements legal provisions legal provisions consist number separate legal matters including claims arising trade various group companies nature amounts timings outflows difficult predict part regular review litigation matters management reassessed provisions recorded certain litigation matters based development various litigations notably accutane case provisions previously held released resulting income chf million major element legal expenses show net income chf million net expense chf million details major legal cases outstanding disclosed environmental provisions provisions environmental matters include various separate environmental issues number countries nature amounts timings outflows difficult predict significant provisions discounted time value money material significant provisions relate us site nutley new jersey divested september estimated remediation costs landfill site near grenzach germany used manufacturing operations closed years ago estimated remediation costs manufacturing site clarecastle ireland expected costs environmental remediation clarecastle site reassessed accordingly environmental provisions increased chf million major element environmental expenses show net expense chf million net expense chf million groups procedures environmental protection included annual report pages include actions taken group regard climate change notably groups commitment reduce greenhouse gas emissions restructuring provisions arise planned programmes materially change scope business undertaken group manner business conducted provisions include costs necessarily entailed restructuring associated recurring activities group timings cash outflows reasonably certain provisions discounted time value money material matters pharmaceuticals division significant provisions relate strategic realignment manufacturing network including exiting four manufacturing sites resourcing flexibility plans address various future challenges including biosimilar competition research development strategic alignment outsourcing functions shared service centres external providers see note contingent consideration provisions group party certain contingent consideration arrangements arising business combinations significant provisions discounted using average discount rate time value money material additional details measurement main movements provisions total potential payments arrangements provided note roche finance report notes roche group consolidated financial statements roche group provisions provisions relate items shown table exception employee provisions timing cash outflows nature uncertain provisions millions chf employee provisions sales returns items total provisions contingent liabilities operations earnings group continue time time varying degrees affected political legislative fiscal regulatory developments including relating environmental protection countries operates industries group operates also subject risks various kinds nature frequency developments events covered insurance well effect future operations earnings predictable group entered strategic alliances various companies order gain access potential new products utilise companies help develop groups potential new products potential future payments may become due certain collaboration partners achieving certain milestones defined collaboration agreements groups best estimates future commitments payments given note pharmaceuticals legal cases december provisions legal cases pharmaceuticals division chf million chf million provisions recorded cases settled mainly relating matters listed accutane hoffmannla roche inc hlr various roche affiliates named defendants numerous legal actions us elsewhere relating acne medication accutane litigation alleges accutane caused certain serious conditions including limited inflammatory bowel disease ibd birth defects psychiatric disorders hlr announced following reevaluation portfolio medicines available generic manufacturers rapidly declining brand sales us high costs personalinjury lawsuits continues defend vigorously decided immediately discontinue manufacture distribution product us actions pending federal court alleging ibd consolidated pretrial proceedings multidistrict litigation mdl us district court middle district florida tampa division august mdl closed pendency mdl district court granted summary judgment favour hlr federal ibd cases proceeded affirmed us court appeals eleventh circuit actions pending state court new jersey alleging ibd consolidated pretrial proceedings superior court new jersey law division atlantic county december one case appeal usd million jury new jersey superior court ruled favour plaintiff subsequently verdict reversed favour hlr january new jersey supreme court reinstated case remanded appellate division consideration issues may appellate division ruled favour hlr reversed verdict remanded new trial plaintiff filed petition review supreme court remains pending february superior court new jersey law division atlantic county held eightday evidentiary hearing whether plaintiffs experts testify accutane causes crohns disease february superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing prejudice agreedupon list crohns disease cases subject superior courts february order july new jersey appellate division reversed order excluding plaintiffs experts testifying accutane causes crohns disease reinstated dismissed cases finding trial court wrongfully barred plaintiffs expert witnesses hlr filed petition review new jersey supreme court granted december oral argument expected roche finance report roche group notes roche group consolidated financial statements may superior court entered order granting summary judgment dismissing cases filed new jersey residents basis drug label adequate matter law since july superior court granted hlrs motion summary judgment adequacy label post ingestion cases jurisdictions superior court applied new jersey law jurisdictions granted hlrs motion dismissing approximately cases alternative superior court applied home state law granted summary judgment jurisdictions denied jurisdictions would resulted cases dismissed july new jersey appellate division affirmed dismissal cases reinstated judgments cases based strength hlrs warnings hlr dismissed plaintiffs filed petitions review new jersey supreme court granted december oral argument expected january october superior court entered orders granting summary judgment dismissing cases failure prove accutane proximately caused ulcerative colitis plaintiffs appealed decisions february march superior court new jersey law division atlantic county held evidentiary hearing whether plaintiffs experts testify accutane causes ulcerative colitis april superior court barred plaintiffs experts methods meet requirements scientific reliability may superior court entered order dismissing ulcerative colitis cases subject superior courts april order plaintiffs appealed decisions december hlr defending approximately actions involving approximately plaintiffs brought various state courts throughout us personal injuries allegedly resulting use accutane approximately cases appeal cases survive appeals additional trials may scheduled individual trial results depend variety factors including many unique particular case therefore trial results date may predictive future trial results group continues defend vigorously remaining personal injury cases claims based development litigation provisions previously held released avastinlucentis investigations february italian antitrust authority agcm announced investigation determine whether roche genentech novartis entered agreement restrict competition italian market drugs reference particular avastin marketed roche lucentis marketed novartis avastin lucentis two different drugs developed approved different therapeutic purposes contain different active pharmaceutical ingredients march agcm issued verdict alleges roche novartis colluded artificially differentiate avastin lucentis order foster sales lucentis italy agcm fined roche eur million novartis eur million roche appealed agcm verdict tribunale amministrativo regionale del lazio tar december tar upheld decision agcm roche strongly disagrees verdict tar appealed consiglio di stato may italian ministry health notified roche spa intention seek damages related matter july roche paid eur million fine protest avoid additional penalty fees recorded expense within general administration fine related interest reimbursed roche wins case january european court justice rendered decision five questions referred european court justice consiglio di stato principles defined decision used consiglio di stato render final verdict case outcome matters determined time pdl inhibitor litigation july bristolmyers squibb co bms filed lawsuit genentech delaware bms alleges genentechs sale tecentriq infringes us patent bms seeking judgment favour finding wilfulness monetary damages october genentech filed answer counterclaims seeking declaratory judgment invalidity patent outcome matter determined time average wholesale prices litigation hlr roche laboratories inc rli along approximately brand generic pharmaceutical companies named defendants several legal actions us relating pricing pharmaceutical drugs state medicaid reimbursement primary allegation litigations pharmaceutical companies misrepresented otherwise reported inaccurate average wholesale prices awp andor wholesale acquisition costs wac drugs prices allegedly relied upon states calculating medicaid reimbursements entities retail pharmacies states respective attorney general seeking repayment amounts claim overreimbursed time period associated cases december hlr rli defending one awp action filed state new jersey hlr rli vigorously defending trial date set outcome matter determined time rituxan arbitration october genentech biogen idec inc filed complaint california sanofiaventis deutschland gmbh sanofiaventis us llc sanofiaventis us inc sanofi seeking declaratory judgment certain genentech products including rituxan infringe sanofis us patent nos patents invalid sanofi alleged rituxan another genentech product infringe certain claims patents march district court ruled matter law genentech biogen idec infringe asserted patent claims may sanofi appealed courts noninfringement ruling appellate court affirmed district courts judgment patent infringement roche finance report notes roche group consolidated financial statements roche group addition october sanofi affiliate hoechst gmbh hoechst filed icc international court arbitration paris request arbitration genentech relating terminated patentlicence agreement one hoechsts predecessors genentech pertained abovementioned patents related patents outside us hoechst sought payment patent licence royalties sales certain genentech products including rituxan damages breach contract relief various arbitral awards september february arbitrator found genentech liable hoechst patentlicence royalties rituxan awarded royalties interest hoechst sought february group recorded back royalty expense chf million net assumed reimbursement portion groups obligation copromotion partner us hoechst initiated proceedings us france germany seeking enforce arbitral awards october genentech paid awarded royalties interest hoechst protest genentech seeking annulment arbitral awards proceedings initiated court appeal paris hearing proceedings june september paris court appeal stayed annulment proceedings seek guidance eu court justice specific legal question raised genentech relating arbitral awards noncompliance eu competition laws november hoechst filed notices appeal french supreme court seeking review paris court appeals decision seek guidance eu court justice november french supreme court denied hoechsts challenge decision paris court appeal refer specific legal question eu court justice july eu court justice issued opinion case finding licensee may freely terminate licence licence anticompetitive september paris court appeal issued decision dismissing appeal ruling favour hoechst expected matter finally concluded first quarter addition matters listed currently provisions recorded potential future obligations confirmed occurrence nonoccurrence uncertain future events obligation measured sufficient reliability boniva litigation hlr genentech various roche affiliates collectively roche named defendants numerous legal actions us one dismissed case canada relating postmenopausal osteoporosis medication boniva litigations plaintiffs allege boniva caused either osteonecrosis jaw atypical femoral fractures december roche defending approximately actions involving approximately plaintiffs brought federal state courts throughout us personal injuries allegedly resulting use boniva cases early discovery stages litigation individual trial results depend variety factors including many unique particular case roche vigorously defending matters outcome matters determined time ema investigation october european medicines agency ema announced would start infringement procedure investigate allegations regarding alleged breach medicines safety reporting obligations relation centrally authorised medicines november ema announced results pharmacovigilance risk assessment committee assessment roches medicines ema found impact regarding benefitrisk balance roches medicines confirmed benefitrisk profiles based available safety information ema health authorities confirmed medicines remain authorised without changes treatment advice patients healthcare professionals corrective preventative actions resulting inspections implemented reinspection authorities november led certain findings roche addressed accordingly april ema issued report european commission summarises emas findings relation investigation july european commission issued notification ema returning case file ema new period inquiry july ema announced concluded second inquiry sent july final updated report european commission december european commission announced closed infringement procedure without imposing penalty matter concluded hemlibra emicizumab litigation may baxalta inc baxalta subsidiary shire plc filed patent infringement declaratory judgment patent infringement suit us district court district delaware alleging genentech inc chugai pharmaceutical co ltd currently imminently would manufacture use sell offer sale import us hemlibra emicizumab would infringe baxaltas us patent baxalta seeking judgment infringement injunctive monetary relief attorneys fees costs expenses may genentech served complaint genentechs response counterclaims complaint filed june june chugai waived service september chugai filed motion dismiss complaint lack personal jurisdiction november food drug administration fda approved hemlibra emicizumab haemophilia inhibitors use us december baxalta filed motion preliminary injunction seeking prevent genentech marketing selling hemlibra patients us excluding inhibitor patients already treated excluding inhibitor patients less well served existing bypass treatments receive prophylactic bypass treatments outcome matter determined time roche finance report roche group notes roche group consolidated financial statements securities litigation june class action filed united states district court district new jersey roche holding ltd two current officers lawsuit brings claims federal securities laws connection groups public disclosures particular respect matters relating two roches drugs herceptin perjeta substantially similar lawsuits may follow group vigorously defend matter outcome matter determined time arbitration chugai may medical research council lifearc formerly medical research council technology claimants requested arbitration chugai pharmaceutical co ltd arbitrator appointed august sums sought chugai alleged breach obligations collaboration agreement dated august connection development humanised antihuman il receptor monoclonal antibody actemra claimed chugai obliged pay royalties claimants pursuant collaboration agreement chugai considers claims without merit chugai vigorously defend arbitration outcome matter determined time debt debt movements carrying value recognised liabilities millions chf january proceeds issue bonds notes redemption repurchase bonds notes increase decrease commercial paper increase decrease debt changes financing cash flows net gains losses redemption repurchase bonds notes amortisation debt discount financing costs business combinations net foreign currency transaction gains losses currency translation effects changes foreign exchanges rates changes fair values hedging instruments changes december bonds notes commercial paper amounts due banks financial institutions finance lease obligations borrowings total debt longterm debt shortterm debt total debt pledges groups assets connection debt roche finance report notes roche group consolidated financial statements roche group bonds notes recognised liabilities effective interest rates bonds notes millions chf effective interest rate underlying including instrument hedging us dollar notes fixed rate notes due september principal usd billion isin usbc notes due march principal usd billion isin usuam usas notes due september principal usd billion isin usba notes due september principal usd billion isin usbb na notes due january principal usd billion isin usbm notes due september principal usd billion isin usbe na notes due november principal usd billion isin usbj na notes due may principal usd billion isin usbk na notes due january principal usd billion isin usbl na notes due march principal usd billion outstanding usd billion isin usuan usau notes due november principal usd billion isin usbh na us dollar notes floating rate notes due september principal usd billion isin usbd na notes due september principal usd billion isin usaz na euro medium term note programme fixed rate notes due march principal eur billion isin xs notes due june principal eur billion isin xs na notes due march principal usd billion isin xs notes due march principal eur billion outstanding eur billion isin xs notes due february principal eur billion isin xs na notes due august principal gbp billion outstanding gbp billion isin xs na notes due february principal eur billion isin xs na swiss franc bonds fixed rate bonds due march principal chf billion isin ch na bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch na bonds due september principal chf billion isin ch bonds due september principal chf billion isin ch bonds due march principal chf billion isin ch na genentech senior notes senior notes due july principal usd billion outstanding usd billion isin usac na total bonds notes roche finance report roche group notes roche group consolidated financial statements bonds notes maturity millions chf within one year one two years two three years three four years four five years five years total bonds notes unamortised discount included carrying value bonds notes millions chf us dollar notes euro notes swiss franc bonds pound sterling notes total unamortised discount issuance bonds notes march group completed offering chf billion fixed rate bonds issued three tranches chf million bonds zero coupon mature september chf million bonds coupon mature september chf million bonds coupon mature march bonds listed six swiss exchange group received chf million aggregate net proceeds issuance sale fixed rate bonds issuance bonds notes february group issued eur million fixed rate notes coupon euro medium term note programme notes mature february listed luxembourg stock exchange group received chf million aggregate net proceeds issuance sale fixed notes march group completed offering usd billion fixed rate notes coupon notes mature may group received chf million aggregate net proceeds issuance sale fixed notes october group completed offering usd million usd million fixed rate notes coupon respectively notes mature january january respectively group received chf million aggregate net proceeds issuance sale fixed notes roche finance report notes roche group consolidated financial statements roche group redemption repurchase bonds notes redemption swiss franc bonds due date march group redeemed fixed rate bonds principal amount chf billion cash outflow chf million plus accrued interest effective interest rate bonds redemption us dollar notes due date september group redeemed fixed rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes due date september group redeemed floating rate notes principal amount usd billion cash outflow chf million plus accrued interest effective interest rate notes redemption pound sterling notes november group completed tender offer repurchase gbp million fixed rate notes due august cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes redemption euro notes november group completed tender offer repurchase eur million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes additional chf million gain recognised part net gains losses redemption repurchase bonds notes coming termination crosscurrency swap used hedge tendered portion euro notes redemption repurchase bonds notes redemption us dollar notes december group resolved exercise option call early partial redemption fixed rate notes due march march group redeemed outstanding principal usd million amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow chf million plus accrued interest december group revised carrying value notes take account changes amounts timings estimated cash flows resulted increase carrying value usd million chf million recorded within financing costs loss redemption additional chf million loss recorded redemption effective interest rate notes june group resolved exercise option call early partial redemption fixed rate notes due march august group redeemed outstanding principal usd million amount equal sum present values remaining scheduled payments notes discounted redemption date us treasury rate plus together accrued unpaid interest principal cash outflow chf million plus accrued interest loss redemption chf million effective interest rate notes december group completed tender offer repurchase usd million fixed rate notes due march cash outflow chf million plus accrued interest loss repurchase chf million effective interest rate notes redemption euro notes due date march group redeemed fixed rate notes principal eur billion cash outflow chf million plus accrued interest effective interest rate notes roche finance report roche group notes roche group consolidated financial statements cash flows issuance redemption repurchase bonds notes cash inflows issuance bonds notes millions chf euro medium term note programme euro notes us dollar notes swiss franc bonds total cash inflows issuance bonds notes cash outflows redemption repurchase bonds notes millions chf euro medium term note programme pound sterling notes euro medium term note programme euro notes us dollar notes swiss franc bonds total cash outflows redemption repurchase bonds notes commercial paper roche holdings inc commercial paper program roche holdings inc established commercial paper program issue usd billion unsecured commercial paper notes guaranteed roche holding ltd total committed credit lines available backstop supporting commercial paper program usd billion december maturity notes program exceed days date issuance december unsecured commercial paper notes principal amount usd billion average interest rate outstanding movements commercial paper obligations millions chf january net cash proceeds payments currency translation effects december amounts due banks financial institutions amounts denominated various currencies average interest rate december amounts outstanding chf million chf million due within one year roche finance report notes roche group consolidated financial statements roche group equity attributable roche shareholders changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december entire amount transferred income statement reported financial income expense roche finance report roche group notes roche group consolidated financial statements changes equity attributable roche shareholders millions chf reserves retained share capital earnings fair value hedging translation total year ended december january net income recognised income statement availableforsale investments fair value gains losses taken equity transferred income statement income taxes noncontrolling interests cash flow hedges gains losses taken equity transferred income statement income taxes noncontrolling interests currency translation foreign operations exchange differences accumulated differences transferred income statement divestment subsidiaries noncontrolling interests defined benefit plans remeasurement gains losses limit asset recognition income taxes noncontrolling interests comprehensive income net tax total comprehensive income dividends equity compensation plans net transactions equity changes noncontrolling interests december entire amount transferred income statement reported financial income expense genentech transaction group completed purchase noncontrolling interests genentech effective march based international accounting standard separate financial statements ias consistent international financial reporting standard consolidated financial statements ifrs adopted group transaction accounted full equity transaction consequence carrying amount consolidated equity group time reduced chf billion chf billion allocated eliminate book value genentech noncontrolling interests accounting effect significantly impacted groups net equity effect groups business dividend policy roche finance report notes roche group consolidated financial statements roche group share capital december authorised issued share capital roche holding ltd groups parent company consisted million shares nominal value chf preceding year shares bearer shares group maintain register shareholders based information supplied group shareholder group pooled voting rights owns issued shares march shareholder group announced would continue shareholder pooling agreement existing since modified shareholder composition shareholder group pooled voting rights holds shares corresponding shares issued figure include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool described note based information supplied group novartis holding ag basel owns participation issued shares nonvoting equity securities genussscheine december nonvoting equity securities authorised issue preceding year swiss company law nonvoting equity securities nominal value part share capital issued contribution would shown asset balance sheet roche holding ltd nonvoting equity security confers rights shares participate net profit remaining proceeds liquidation following repayment nominal value shares participation certificates accordance law articles incorporation roche holding ltd company entitled times exchange nonvoting equity securities shares participation certificates dividends march shareholders approved distribution dividend chf per share nonvoting equity security chf respect business year distribution holders outstanding shares nonvoting equity securities totalled chf million chf million recorded retained earnings board directors proposed dividends business year chf per share nonvoting equity security approved would result total distribution shareholders chf million subject approval annual general meeting march equity instruments holdings equity instruments equivalent number nonvoting equity securities millions millions shares nonvoting equity securities total equity instruments recorded within equity original purchase cost december fair value shares chf million fair value nonvoting equity securities chf billion equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note reserves fair value reserve fair value reserve represents cumulative net change fair value availableforsale financial assets asset sold impaired otherwise disposed hedging reserve hedging reserve represents effective portion cumulative net change fair value cash flow hedging instruments related hedged transactions yet occurred translation reserve translation reserve represents cumulative currency translation differences relating consolidation group companies use functional currencies swiss francs roche finance report roche group notes roche group consolidated financial statements subsidiaries associates chugai effective october roche group chugai completed alliance create leading researchdriven japanese pharmaceutical company formed merger chugai roches japanese pharmaceuticals subsidiary nippon roche merged company known chugai consolidated subsidiary chugai fully consolidated subsidiary group based groups interest chugai december roche relationship chugai founded basic alliance licensing research collaboration agreements common stock chugai publicly traded listed tokyo stock exchange stock code tse chugai prepares financial statements accordance international financial reporting standards ifrs filed quarterly basis tokyo stock exchange due certain consolidation entries minor differences chugais standalone ifrs results results chugai consolidated roche group accordance ifrs chugai summarised financial information millions chf income statement sales royalties operating income total revenues operating profit balance sheet noncurrent assets current assets noncurrent liabilities current liabilities total net assets cash flows cash flows operating activities cash flows investing activities cash flows financing activities dividends dividends distributed third parties holding chugai shares totalled chf million chf million recorded noncontrolling interests see note dividends paid chugai roche eliminated consolidation intercompany items roches relationship chugai chugai entered certain agreements roche discussed basic alliance agreement part basic alliance agreement signed december roche chugai entered certain arrangements covering future operation governance chugai amongst matters cover following areas structuring alliance roches rights shareholder roches rights nominate members chugais board directors certain limitations roches ability buy sell chugais common stock chugai issues additional shares common stock connection convertible debt equity compensation plans may issue additional shares purposes affects roches percentage ownership interest basic alliance agreement provides amongst matters chugai guarantee roches right maintain shareholding percentage chugai less roche finance report notes roche group consolidated financial statements roche group licensing agreements japan umbrella rights agreement signed december chugai exclusive rights market roches pharmaceutical products japan chugai also right first refusal development marketing japan development compounds advanced roche rest world umbrella rights agreement excluding japan south korea signed may revised amended restated rest world umbrella rights agreement excluding japan south korea taiwan signed august agreement roche right first refusal development marketing chugais development compounds markets outside japan excluding south korea taiwan agreements roche chugai signed series separate agreements certain specific products depending specific circumstances terms agreement may result payments arms length basis roche chugai following matters upfront payments right first refusal license product exercised milestone payments dependent upon achievement agreed performance targets royalties future product sales specific product agreements may also cover manufacture supply respective products meet partys clinical andor commercial requirements arms length basis research collaboration agreements roche chugai entered research collaboration agreements areas small molecule synthetic drug research biotechnologybased drug discovery foundation medicine april group acquired controlling interest foundation medicine inc fmi publicly owned us company based cambridge massachusetts entered investor rights agreement research development collaboration agreement several commercial collaboration agreements fmi fully consolidated subsidiary group based groups interest fmi december roche relationship fmi founded agreements common stock fmi publicly traded listed nasdaq stock code fmi fmi prepares financial statements accordance us gaap filed quarterly basis sec due certain consolidation entries differences fmis standalone us gaap results results fmi consolidated roche group accordance ifrs dividends dividends distributed third parties holding fmi shares associates june group acquired interest senseonics holding inc senseonics publicly owned us company based germantown maryland resulted group interest senseonics investment assessed treated associate group groups interest senseonics december common stock senseonics publicly traded listed new york stock exchange nysemkt stock code sens senseonics prepares financial statements accordance us gaap filed quarterly basis sec group accounts senseonics using equity method based senseonics financial statements publicly available groups share senseonics results loss chf million included financial income expenses see note carrying value groups share senseonics net assets december asset chf million included noncurrent assets see note divestment subsidiaries february group sold wholly owned subsidiary roche carolina inc florence us third party part previously announced pharmaceuticals divisions strategic realignment manufacturing network total consideration received usd million cash total loss divestment chf million reported global restructuring costs roche pharmaceuticals operating segment included general administration roche finance report roche group notes roche group consolidated financial statements september group sold wholly owned subsidiary segrate site italy third party part previously announced pharmaceuticals divisions strategic realignment manufacturing network total consideration eur million eur million received remaining eur million received total loss divestment chf million reported global restructuring costs roche pharmaceuticals operating segment included general administration total gains losses divestments shown table gains losses divestment subsidiaries millions chf consideration property plant equipment net assets liabilities currency translation foreign operations transferred income statement total net assets disposed provisions accruals residual obligations retained group gains losses divestment subsidiaries noncontrolling interests changes equity attributable noncontrolling interests millions chf january net income recognised income statement chugai noncontrolling interests total net income recognised income statement availableforsale investments cash flow hedges currency translation foreign operations remeasurements defined benefit plans comprehensive income net tax total comprehensive income business combinations dividends noncontrolling shareholders chugai noncontrolling interests equity compensation plans net transactions equity changes noncontrolling interests equity contribution noncontrolling interests december chugai noncontrolling interests total noncontrolling interests roche finance report notes roche group consolidated financial statements roche group employee benefits employee remuneration millions chf wages salaries social security costs defined contribution plans operating expenses defined benefit plans equity compensation plans termination costs employee benefits employee remuneration included operating results net interest cost defined benefit plans total employee remuneration employee benefits consist mainly life insurance schemes certain insurance schemes providing medical coverage longterm shortterm disability benefits pensions postemployment benefits groups objective provide attractive competitive postemployment benefits employees time ensuring various plans appropriately financed managing potential impacts groups longterm financial position employees covered pension plans sponsored group companies nature plans varies according legal regulations fiscal requirements market practice countries employees employed postemployment benefit plans classified ifrs defined contribution plans group pays fixed contributions separate fund thirdparty financial institution legal constructive obligation pay contributions plans classified defined benefit plans defined contribution plans defined contribution plans funded payments employees group funds administered third parties groups expenses plans chf million chf million assets liabilities recognised groups balance sheet respect plans apart regular prepayments accruals contributions withheld employees wages salaries groups contributions groups major defined contribution plan us roche k savings plan defined benefit plans plans usually established trusts independent group funded payments group companies employees cases notably major defined benefit plans germany plans unfunded group pays pensions retired employees directly financial resources plans usually governed senior governing body board trustees typically composed employee employer representatives funding plans determined local regulations using independent actuarial valuations separate independent actuarial valuations prepared accordance requirements ias use groups financial statements groups major pension plans located switzerland us germany total account groups defined benefit obligation roche finance report roche group notes roche group consolidated financial statements pension plans switzerland current pension arrangements employees switzerland made plans governed swiss federal occupational old age survivors disability pension act bvg groups pension plans administered separate legal foundations funded regular employee company contributions final benefit contributionbased certain minimum guarantees due minimum guarantees swiss plans treated defined benefit plans purposes ifrs financial statements although many characteristics defined contribution plans underfunding may remedied various measures increasing employee company contributions lowering interest rate retirement account balances reducing prospective benefits suspension early withdrawal facility operating income chf million recorded past service costs changes groups pension plans switzerland announced june represents impact adjustment pension liability plan changes amount chf million recorded pharmaceuticals division chf million diagnostics division chf million corporate past service income recorded within general administration part adjustments pension plans switzerland group made payments chf million pension funds pension plans us groups major defined benefit plans us closed new members since new employees us join defined contribution plan largest remaining defined benefit plans funded pension plans together smaller unfunded supplementary retirement plans benefits based highest average annual rate earnings specified period length employment plans noncontributory employees group making periodic payments plans underfunding would normally remedied additional company contributions payments made group usd million usd million decrease payments compared due additional contributions made benefit lower insurance fee pension benefit guaranty corporation us government agency overseeing occupational pension schemes us group entered annuity buyout agreement insurance company paid usd million plan assets settle defined benefit obligation retired employees led settlement loss usd million pension plans germany groups major pension arrangements germany governed occupational pensions act betravg plans unfunded group pays pensions retired employees directly financial resources plans noncontributory employees benefits based final salary length employment plans closed new members since replaced new plan funded regular employee company contributions administered contractual trust agreement final benefit contributionbased minimum guarantee due minimum guarantee plan treated defined benefit plan purposes ifrs financial statements although many characteristics defined contribution plan pension plans rest world represent approximately groups defined benefit obligation consist number smaller plans various countries largest pension plans chugai independently managed chugai main pension plan united kingdom chugai plans fully described chugais ifrs financial statements uk pension plan funded regular employee company contributions benefits based final salary length employment plan closed new members since replaced defined contribution plan group made payments eur million pension funds ireland relation restructuring manufacturing site clarecastle ireland measures taken group entered annuity buyout agreement insurance company paid eur million plan assets settle defined benefit obligation retired employees addition transfer value payments eur million plan assets made deferred employees settle defined benefit obligation group recorded settlement loss eur million transactions postemployment benefit opeb plans represent approximately groups defined benefit obligation consist postemployment healthcare life insurance schemes mainly us plans mainly unfunded andor contributory employees group reimbursing retired employees directly financial resources groups major opeb plans us closed new members since part costs plans reimbursable medicare prescription drug improvement modernization act statutory funding requirement plans group funding plans extent tax efficient payments made group plans none december ifrs funding status including reimbursement rights funded opeb plans us roche finance report notes roche group consolidated financial statements roche group defined benefit plans income statement millions chf post post pension employment total pension employment total plans benefit plans expense plans benefit plans expense current service cost past service income cost settlement gain loss total operating expenses net interest cost defined benefit plans total expense recognised income statement funding status funding groups various defined benefit plans responsibility senior governing body board trustees sponsoring employer managed based local statutory valuations follow legislation requirements respective jurisdiction plan established qualified independent actuaries carry statutory actuarial valuations regular basis actuarial assumptions determining funding status statutory basis regularly assessed local senior governing body funding status closely monitored corporate level unfunded plans mainly groups german affiliates fully reserved pension obligations invested local affiliates operations ifrs funding status funded defined benefit plans improved reimbursement rights linked postemployment medical plans us represent expected reimbursement medical expenditure provided medicare prescription drug improvement modernization act defined benefit plans funding status millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total funded plans fair value plan assets defined benefit obligation funding unfunded plans defined benefit obligation total funding status limit asset recognition reimbursement rights net recognised asset liability reported balance sheet defined benefit plan assets defined benefit plan liabilities roche finance report roche group notes roche group consolidated financial statements plan assets responsibility investment strategies funded plans senior governance body board trustees assetliability studies performed regularly major pension plans studies examine obligations postemployment benefit plans evaluate various investment strategies respect key financial measures expected returns expected risks expected contributions expected funded status plan interdependent way goal assetliability study select appropriate asset allocation funds held within plan investment strategy developed optimise expected returns manage risks contain fluctuations statutory funded status assetliability studies include strategies match cash flows assets plan obligations group currently use longevity swaps manage longevity risk plan assets managed using internal external asset managers actual performance continually monitored pension fund governance bodies well closely monitored corporate level financial statements difference interest income actual return plan assets remeasurement recorded directly comprehensive income actual return plan assets gain chf million gain chf million recognition plan assets limited present value economic benefits available refunds plans reductions future contributions plans defined benefit plans fair value plan assets reimbursement rights millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january interest income plan assets remeasurements plan assets currency translation effects employer contributions employee contributions benefits paid funded plans benefits paid settlements administration costs december defined benefit plans composition plan assets millions chf equity securities debt securities property cash money market instruments investments december assets invested variety different classes order maintain balance risk return follows equity debt securities mainly quoted market prices level fair value hierarchy property mainly private commercial property funds mainly observable inputs level fair value hierarchy cash money market instruments mainly invested financial institutions credit rating lower investments mainly consist alternatives mortgages commodities insurance contracts used risk management purposes mainly observable inputs level fair value hierarchy unobservable inputs level fair value hierarchy included within fair value plan assets groups shares nonvoting securities fair value chf million chf million debt instruments issued group fair value chf million chf million roche finance report notes roche group consolidated financial statements roche group defined benefit obligation defined benefit obligation calculated using projected unit credit method reflects service rendered employees dates valuation incorporates actuarial assumptions primarily regarding discount rates used determining present value benefits projected rates remuneration growth mortality rates present value defined benefit obligation determined discounting estimated future cash outflows using interest rates highquality corporate bonds government bonds countries deep market corporate bonds corporate government bonds denominated currency benefits paid maturity terms approximating terms related pension obligation groups final salarybased defined benefit pension plans us germany united kingdom closed new participants active employees members pension plans time closed new participants continue accrue benefits final salarybased defined benefit pension plans new employees us uk join groups defined contribution plans new employees germany join contributionbased plan minimum guarantee result proportion defined benefit obligation relates closed plans expected decrease future defined benefit pension plans switzerland final benefit contributionbased minimum guarantee remain open new employees defined benefit plans defined benefit obligation millions chf post post pension employment pension employment plans benefit plans total plans benefit plans total january current service cost interest cost remeasurements demographic assumptions financial assumptions experience adjustments currency translation effects employee contributions benefits paid funded plans benefits paid unfunded plans benefits paid settlements past service income cost settlement gain loss december composition plan active members deferred vested members retired members december plans geography switzerland united states germany rest world december duration years roche finance report roche group notes roche group consolidated financial statements actuarial assumptions actuarial assumptions used financial statements based requirements set ias employee benefits unbiased mutually compatible estimates variables determine ultimate cost providing postemployment benefits set annual basis local management based advice actuaries subject approval corporate management groups actuaries actuarial assumptions consist demographic assumptions matters mortality employee turnover financial assumptions matters interest rates salary benefit levels inflation rates costs medical benefits actuarial assumptions vary based upon local economic social conditions actuarial assumptions used various statutory valuations may differ based local legal regulatory requirements demographic assumptions significant demographic assumptions relate mortality rates groups actuaries use mortality tables take account historic patterns expected changes increases longevity rates employee turnover disability early retirement based historical behaviour average life expectancy assumed individual age follows defined benefit plans average life expectancy age major schemes years male female country mortality table switzerland bvg projected cmi model united states rp projected mp germany heubeck tables g mortality assumptions used pension plans switzerland based bvg applying continuous mortality investigation cmi model longterm rate used longevity improvements financial assumptions based market expectations period obligations settled assumptions used actuarial valuations shown defined benefit plans financial actuarial assumptions weighted weighted average range average range discount rates expected rates salary increases expected rates pension increases expected inflation rates immediate medical cost trend rate ultimate medical cost trend rate discount rates determined reference interest rates highquality corporate bonds government bonds countries deep market corporate bonds expected rates salary increases based expected inflation rates adjustment reflect groups latest expectation longterm real salary increases expected rates pension increases generally linked expected inflation rate funding status plan expected inflation rates derived looking level inflation implied financial markets conjunction economists price inflation forecasts historic price inflation well economic variables circumstances medical cost trend rates take account benefits set plan terms expected future changes medical costs since groups major postemployment medical plans us employees rates driven developments us sensitivity analysis measurement net defined benefit obligation particularly sensitive changes discount rate inflation rate expected mortality medical cost trend rate assumptions following table summarises impact change assumptions present value defined benefit obligation roche finance report notes roche group consolidated financial statements roche group defined benefit plans sensitivity defined benefit obligation actuarial assumptions millions chf increase decrease defined benefit obligation year increase life expectancy discount rates increase decrease expected inflation rates increase decrease immediate medical cost trend rate increase decrease sensitivity analysis considers change one assumption time leaving assumptions unchanged approach shows isolated effect changing one individual assumption take account assumptions related method used carry sensitivity analysis prior year cash flows group incurred cash flows defined benefit plans shown table defined benefit plans cash flows millions chf employer contributions net reimbursements funded plans benefits paid unfunded plans total cash inflow outflow based recent actuarial valuations group expects employer contributions funded plans approximately chf million includes estimated chf million additional contributions mostly related us defined benefit plans benefits paid unfunded plans estimated approximately chf million mostly relate german defined benefit plans roche finance report roche group notes roche group consolidated financial statements equity compensation plans group operates several equity compensation plans including separate plans chugai foundation medicine ifrs share based payment requires fair value equity compensation plan awards granted employees estimated grant date recorded expense vesting period expenses equity compensation plans millions chf cost sales marketing distribution research development general administration total operating expenses equity compensation plans roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan roche connect roche option plan bonus stock awards chugai foundation medicine plans total operating expenses equitysettled cashsettled cash inflow outflow equity compensation plans millions chf roche option plan exercises chugai foundation medicine plans exercises roche connect costs transactions equity total cash inflow outflow equitysettled equity compensation plans net transactions equity net cash outflow transactions equity mainly arises sales purchases equity instruments held groups potential conversion obligations may arise groups equity compensation plans see note equity compensation plans roche stocksettled stock appreciation rights group issues stocksettled stock appreciation rights ssars certain directors management employees selected discretion group ssars give employees right receive non voting equity securities reflecting value appreciation market price nonvoting equity securities grant date exercise date roche ssar plan million ssars available issuance tenyear period rights nontradable equitysettled awards sevenyear duration vest phased basis three years roche finance report notes roche group consolidated financial statements roche group roche ssars movement number rights outstanding weighted average weighted average number rights exercise price number rights exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche ssars terms rights outstanding december rights outstanding rights exercisable number weighted average weighted average number weighted average outstanding years remaining exercise price exercisable exercise price year grant thousands contractual life chf thousands chf total roche restricted stock unit plan group issues restricted stock units rsus awards certain directors management employees selected discretion group rsus nontradable represent right receive nonvoting equity securities vest threeyear period subject performance conditions currently performance conditions outstanding rsus december roche rsu plan million nonvoting equity securities available issuance tenyear period roche rsu plan also includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number nonvoting equity securities individual award granted roche rsus movement number awards outstanding number awards number awards thousands thousands outstanding january granted forfeited transferred participants outstanding december vested transferable roche performance share plan group offers future share nonvoting equity security awards discretion board directors cash equivalent certain directors key senior managers nontradable equitysettled awards programme currently operates annual threeyear cycles roche performance share plan psp includes value adjustment amount equivalent sum shareholder distributions made group vesting period attributable number shares nonvoting equity securities individual award granted amount shares nonvoting equity securities allocated depend upon individuals salary level achievement performance targets linked groups total shareholder return shares nonvoting equity securities combined relative groups peers threeyear period date grant discretion board directors award result zero two shares non voting equity securities value adjustment depending upon achievement performance targets roche finance report roche group notes roche group consolidated financial statements roche performance share plan terms outstanding awards december number awards outstanding thousands vesting period years years years allocated recipients feb feb feb fair value per unit grant chf total fair value grant chf millions roche connect programme enables employees worldwide except us certain countries make regular deductions salaries purchase nonvoting equity securities administered independent third parties group contributes programme allows employees purchase nonvoting equity securities discount usually administrator purchases necessary nonvoting equity securities directly market december administrator held million nonvoting equity securities million cost plan chf million chf million roche option plan programme used countries ssars used awards plan give employees right purchase nonvoting equity securities exercise price specified grant date options nontradable equity settled awards sevenyear duration vest phased basis three years roche option plan movement number options outstanding weighted average weighted average number options exercise price number options exercise price thousands chf thousands chf outstanding january granted forfeited exercised expired outstanding december exercisable roche option plan terms options outstanding december options outstanding options exercisable weighted average weighted average weighted average number outstanding years remaining exercise price number exercisable exercise price year grant thousands contractual life chf thousands chf total weighted average share price roche nonvoting equity securities year chf chf bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date roche finance report notes roche group consolidated financial statements roche group fair value measurement inputs used measurement fair values grant date equity compensation plans follows fair value measurement roche roche roche stocksettled stock restricted performance roche appreciation rights stock unit plan share plan option plan progressively cliff vesting cliff vesting progressively vesting period years years years years contractual life years na na years number granted year thousands weighted average fair value chf model used binomial market price monte carlo b binomial inputs option pricing model share price grant date chf exercise price chf expected volatility c na na expected dividend yield na na early exercise factor na na expected exit rate na na fair value roche rsus equivalent share price date grant b input parameters covariance matrix roche individual companies peer group based threeyear history riskfree interest rate minus valuation takes account defined rank performance structure determines payout plan c volatility determined primarily reference historically observed prices underlying equity riskfree interest rates derived zero coupon swap rates grant date taken datastream early exercise factor describes ratio expected market price exercise date exercise price early exercises expected based historically observed behaviour earnings per share nonvoting equity security basic earnings per share nonvoting equity security net income attributable roche shareholders chf millions number shares millions number nonvoting equity securities millions weighted average number shares nonvoting equity securities held millions weighted average number shares nonvoting equity securities issue millions basic earnings per share nonvoting equity security chf roche finance report roche group notes roche group consolidated financial statements diluted earnings per share nonvoting equity security net income attributable roche shareholders chf millions increase noncontrolling interests share group net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue millions adjustment assumed exercise equity compensation plans dilutive millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions diluted earnings per share nonvoting equity security chf statement cash flows cash flows operating activities cash flows operating activities arise groups primary activities pharmaceuticals diagnostics divisions calculated indirect method adjusting groups operating profit operating income expenses cash flows example depreciation amortisation impairment order derive cash generated operations operating cash flows shown statement cash flows operating cash flows also include income taxes paid activities cash generated operations millions chf net income add back nonoperating income expense financing costs financial income expense income taxes operating profit depreciation property plant equipment amortisation intangible assets impairment goodwill impairment intangible assets impairment reversal property plant equipment operating income expense defined benefit plans operating expense equitysettled equity compensation plans net income expense provisions bad debt reversal expense inventory writedowns inventory fair value adjustment net gain loss disposal products adjustments cash generated operations roche finance report notes roche group consolidated financial statements roche group cash flows investing activities cash flows investing activities principally arising groups investments property plant equipment intangible assets acquisition divestment subsidiaries associates businesses cash flows connected groups portfolio marketable securities investments also included interest dividend payments received respect securities investments cash flows indicate groups net reinvestment operating assets cash flow effects business combinations divestments well cash generated groups investments interest dividends received millions chf interest received dividends received total cash flows financing activities cash flows financing activities primarily proceeds issue repayment groups equity debt instruments also include interest payments dividend payments instruments cash flows shortterm financing including finance leases also included cash flows indicate groups transactions providers equity debt financing cash flows shortterm borrowings shown net movement consist large number transactions short maturity dividends paid millions chf dividends roche group shareholders dividends noncontrolling shareholders chugai dividends noncontrolling shareholders increase decrease dividends payable dividend withholding tax total liabilities arising financing activities movements carrying value recognised assets liabilities millions chf cash flows noncash changes foreign outflow financing business fair value exchange january inflow costs combinations rates december debt interest payable derivative financial instruments net cash collateral receivables payables net total debt interest payable derivative financial instruments net cash collateral receivables payables net total roche finance report roche group notes roche group consolidated financial statements significant noncash transactions significant noncash transactions none except contingent consideration arrangements arising business combinations see notes risk management group risk management risk management fundamental element groups business practice levels encompasses different types risks group level risk management integral part longterm forecasting controlling processes material risks monitored regularly discussed corporate executive committee audit committee board directors financial risk management group exposed various financial risks arising underlying operations corporate finance activities groups financial risk exposures predominantly related changes foreign exchange rates interest rates equity prices well creditworthiness solvency groups counterparties financial risk management within group governed policies reviewed boards directors roche chugai foundation medicine appropriate areas statutory responsibility policies cover credit risk liquidity risk market risk policies provide guidance risk limits type authorised financial instruments monitoring procedures general principle policies prohibit use derivative financial instruments speculative trading purposes policy implementation daytoday risk management carried relevant treasury functions regular reporting risks performed relevant accounting controlling functions within roche chugai foundation medicine credit risk credit risk arises possibility counterparties transactions may default obligations causing financial losses group objective managing counterparty credit risk prevent losses liquid funds deposited invested counterparties maximum exposure credit risk resulting financial activities without considering netting agreements without taking account collateral held credit enhancements equal carrying value groups financial assets accounts receivable december group trade receivables chf billion chf billion subject policy active credit risk management focuses assessment country risk credit availability ongoing credit evaluation account monitoring procedures objective trade receivables management maximise collection unpaid amounts december groups combined trade receivables balance three us national wholesale distributors mckesson corp amerisourcebergen corp cardinal health inc equivalent chf billion representing groups consolidated trade receivables chf billion representing significant concentration counterparty credit risk due groups large number customers wide geographical spread risk limits exposures continuously monitored country nature counterparties group obtains credit insurance similar enhancements appropriate protect collection trade receivables december collateral held trade receivables none roche finance report notes roche group consolidated financial statements roche group since financial difficulties southern european countries notably spain italy greece portugal group leading supplier healthcare sectors countries trade receivables chf billion chf billion public private customers countries group uses different measures improve collections countries including intense communication customers factoring negotiations payments plans charging interest late payments legal action nature geographic location counterparties accounts receivable overdue impaired shown table include balances us national wholesalers southern europe public customers described accounts receivable overdue nature geographical location counterparties millions chf whole whole salers salers regions total public distributors private total public distributors private switzerland europe north america latin america japan asia australia oceania rest world total ageing accounts receivable impaired shown table ageing accounts receivable impaired millions chf neither overdue impaired overdue month overdue months overdue months overdue months overdue year total accounts receivable cash marketable securities december group cash marketable securities chf billion chf billion subject policy restricting exposures highquality counterparties setting defined limits individual counterparties limits counterparty credit ratings reviewed regularly investments marketable securities entered basis guidelines regard liquidity quality maximum amount general rule group invests highquality securities adequate liquidity cash shortterm time deposits subject rules limit groups exposure individual financial institutions rating analysis cash fixed income marketable securities market values chf total chf total aaa range aa range range bbb range bbb range unrated total roche finance report roche group notes roche group consolidated financial statements master netting agreements group enters derivative transactions collateral agreements international swaps derivatives association isda master netting agreements respective counterparties order mitigate counterparty risk agreements amounts owed counterparty single day respect transactions outstanding currency aggregated single net amount payable one party isda agreements meet criteria offsetting balance sheet group currently enforceable right offset recognised amounts right offset enforceable occurrence future events default credit events contract terms december significant financial assets whose terms renegotiated none impairment losses total impairment losses availableforsale financial assets amounted chf million chf million liquidity risk liquidity risk arises surplus financial obligations available financial assets due point time groups approach liquidity risk maintain sufficient readily available reserves order meet liquidity requirements point time roche chugai enjoy strong credit quality rated least one major credit rating agency ratings permit efficient access international capital markets event major financing requirements december group unused committed credit lines various financial institutions totalling chf billion chf billion chf billion serve backstop line commercial paper program remaining undiscounted cash flow contractual maturities financial liabilities including estimated interest payments shown table contractual maturities financial liabilities millions chf carrying less value total year years years years year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities takeorpay commitments group entered contract manufacturing agreements various companies develop manufacturing capacity flexibility mainly pharmaceuticals division future minimum takeorpay commitments within agreements total potential commitment group chf billion december chf billion roche finance report notes roche group consolidated financial statements roche group market risk market risk arises changing market prices mainly foreign exchange rates interest rates groups financial assets financial liabilities affect groups financial result equity valueatrisk group uses valueatrisk var measure impact market risk financial instruments var indicates value range within given financial instrument fluctuate preset probability result movements market prices var calculated using historical simulation approach scenario financial instruments fully valued total change value earnings determined var calculations based confidence level holding period trading days past ten years holding period reflects time required change corresponding risk exposure deemed appropriate actual future gains losses associated treasury activities may differ materially var analyses due inherent limitations associated predicting timing amount changes interest rates foreign exchange rates equity investment prices particularly periods high market volatilities furthermore var include effect changes credit spreads market risk financial instruments millions chf var interest rate component var foreign exchange component var price component diversification var total market risk interest rate component remained largely stable foreign exchange component decreased due favourable exposure mix price component arises mainly movements equity security prices remained largely stable foreign exchange risk group uses swiss franc reporting currency result exposed movements foreign currencies mainly us dollar japanese yen euro objective groups foreign exchange risk management activities preserve economic value current future assets minimise volatility groups financial result primary focus groups foreign exchange risk management activities hedging transaction exposures arising foreign currency flows monetary positions held foreign currencies group uses forward contracts foreign exchange options crosscurrency swaps hedge transaction exposures application instruments intends continuously lock favourable developments foreign exchange rates thereby reducing exposure potential future movements rates interest rate risk group mainly raises debt fixed rate basis bonds notes group exposed movements interest rates mainly us dollar swiss franc euro floating rate financial instruments primary objective groups interest rate management protect net interest result group may use forward contracts options swaps hedge interest rate exposures depending interest rate environment major currencies group use instruments generate appropriate mix fixed floating rate exposures roche finance report roche group notes roche group consolidated financial statements price risk price risk arises mainly movements prices equity securities group manages price risk placing limits individual total equity investments limits defined percentage total liquid funds absolute number individual equity investments capital management group defines capital manages groups total capitalisation sum debt plus equity including noncontrolling interests groups objectives managing capital safeguard groups ability continue going concern continue provide benefits patients returns investors provide adequate return investors based level risk undertaken available necessary financial resources allow group invest areas may deliver future benefits patients returns investors maintain sufficient financial resources mitigate risks unforeseen events capitalisation reported senior management part groups regular internal management reporting shown table capital millions chf capital reserves attributable roche shareholders equity attributable noncontrolling interests total equity total debt capitalisation groups net equity significantly impacted genentech transaction see note group subject regulatory capital adequacy requirements known financial services industry group majority shareholdings chugai foundation medicine see note chugai foundation medicine public companies objectives policies processes managing capital determined local management roche finance report notes roche group consolidated financial statements roche group financial instrument accounting classifications fair values fair values financial assets liabilities together carrying value shown consolidated balance sheet follows carrying value fair value financial instruments millions chf fair value total available hedging fair value loans financial carrying forsale instruments designated receivables liabilities value fair value year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities year ended december noncurrent assets availableforsale investments financial noncurrent assets accounts receivable marketable securities cash cash equivalents current assets derivative financial instruments financial current assets total financial assets debt bonds notes debt contingent consideration accounts payable derivative financial instruments total financial liabilities fair value bonds notes level calculated based observable market prices debt instruments present value future cash flows instrument discounted market rate interest instruments similar credit status cash flows maturity periods roche finance report roche group notes roche group consolidated financial statements fair value hierarchy table analyses financial instruments carried fair value valuation method different levels defined follows level quoted prices unadjusted active markets identical assets liabilities level observable inputs quoted prices active markets identical assets liabilities level unobservable inputs fair value hierarchy financial instruments millions chf level level level total year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value year ended december marketable securities equity securities debt securities money market instruments time accounts three months derivative financial instruments availableforsale investments held fair value financial assets recognised fair value derivative financial instruments contingent consideration financial liabilities recognised fair value level financial assets consist treasury bills bonds quoted shares level financial assets consist primarily commercial paper certificates deposit derivative financial instruments group determines level fair values using following valuation techniques marketable securities derivative financial instruments based valuation models use observable market data interest rates yield curves foreign exchange rates implied volatilities similar instruments measurement date availableforsale investments based valuation model derived recently published observable financial prices group recognises transfers levels fair value hierarchy end reporting period transfer occurred significant transfers level level vice versa year none roche finance report notes roche group consolidated financial statements roche group level fair values details determination level fair value measurements set contingent consideration arrangements millions chf january arising business combinations utilised settlements total unrealised gains losses included income statement unused amounts reversed additional amount created discount unwind included financing costs total gains losses included comprehensive income currency translation effects december contingent consideration provisions decreased mainly due reversal provisions payment milestones chf million income net mainly reversal remaining provision related seragon acquisition partial reversal provisions mainly related dutalys trophos acquisitions payments chf million made milestones related genia cmi ariosa santaris acquisitions contingent consideration arrangements group party certain contingent consideration arrangements arising business combinations fair values determined considering expected payments discounted present value using riskadjusted average discount rate expected payments determined considering possible scenarios forecast sales performance criteria amount paid scenario probability scenario significant unobservable inputs forecast sales performance criteria riskadjusted discount rate estimated fair value would increase forecast sales performance criteria rates higher riskadjusted discount rate lower december total potential payments contingent consideration arrangements could chf billion chf billion follows potential payments contingent consideration arrangements millions chf acquisition year acquired operating segment trophos roche pharmaceuticals dutalys roche pharmaceuticals santaris roche pharmaceuticals seragon roche pharmaceuticals geneweave diagnostics genia diagnostics ariosa diagnostics cmi diagnostics others diagnostics december derivative financial instruments group entered various currency swaps certain nonus dollar debt instruments cash collateral agreements entered counterparties currency swaps mitigate counterparty risk following table sets carrying value derivative financial instruments amounts subject master netting agreements roche finance report roche group notes roche group consolidated financial statements derivative financial instruments millions chf assets liabilities foreign currency derivatives forward exchange contracts crosscurrency swaps interest rate derivatives swaps derivatives carrying value derivative financial instruments derivatives subject master netting agreements collateral arrangements net amount collateral arrangements november group completed tender offer repurchase eur million fixed rate notes due march result hedge terminated cash received group counterparty movements cash collateral receivable accrued liability millions chf january net cash delivered group fair value currency translation effects december hedge accounting december group following cash flow hedges fair value hedges designated qualifying hedge relationship cash flow hedges group entered crosscurrency swaps hedge foreign exchange interest rate risk bonds notes issued group denominated euro december instruments recorded net fair value liability chf million chf million ineffective portion chugai entered foreign exchange forward contracts hedge part foreign translation exposure swiss franc us dollar december instruments recorded fair value assets chf million fair value assets chf million ineffective portion expected undiscounted cash flows qualifying cash flow hedges including interest payments duration derivative contract final settlement maturity shown table expected cash flows qualifying cash flow hedges millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow roche finance report notes roche group consolidated financial statements roche group undiscounted cash flows table affect profit loss shown include interest payments duration derivative contract include final settlement maturity expected cash flows qualifying cash flow hedges impact profit loss millions chf less less total year year total year year cash inflows cash outflows total cash inflow outflow changes hedging reserve within equity shown note fair value hedges group entered interest rate swaps hedge fixedterm debt instruments december instruments recorded fair value liabilities chf million chf million fair value assets chf million chf million loss chf million recorded interest rate swaps loss chf million fair value hedge highly effective since inception result interest rate swaps largely offset changes fair value hedged debt instruments net investment hedges group net investment hedges related parties controlling shareholders share capital roche holding ltd groups parent company consists bearer shares december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool mr andr hoffmann dr andreas oeri members board directors roche holding ltd mr hoffmann received remuneration totalling chf chf dr oeri received remuneration totalling chf chf transactions group individual members shareholder group exception dr jrg duschmal works postdoc roche subsidiaries associates listing group subsidiaries associates included note listing excludes subsidiaries chugai fmi well material companies notably companies inactive dormant liquidation transactions parent company subsidiaries subsidiaries eliminated consolidation significant transactions group associates roche finance report roche group notes roche group consolidated financial statements key management personnel total remuneration key management personnel chf million chf million members board directors roche holding ltd receive annual remuneration payment time expenses related membership board committees dr franz members corporate executive committee cec roche holding ltd receive remuneration consists annual salary bonus expense allowance group pays social insurance contributions respect remuneration pays contributions pension postemployment benefit plans chairman board directors members cec members cec also participate certain equity compensation plans described terms vesting conditions fair value awards disclosed note new members cec included table full calendar year joined cec similarly members cec retiring part way year included full calendar year left cec remuneration members board directors corporate executive committee millions chf salaries including cashsettled bonus bonus stock awards social security costs pensions postemployment benefits equity compensation plans board fees employee benefits total purposes remuneration disclosures values equity compensation plans including bonus stock awards calculated based fair value used note represent cost group awards grant date reflect amongst matters observed exercise behaviour exit rate whole population receive awards initial simulations performance conditions detailed disclosures regarding executive remuneration required swiss law included remuneration report included annual report pages disclosures values equity compensation plans including bonus stock awards represent fair value employee receives taking account preliminary assessment completed performance conditions fair values shown table reconciles disclosures required swiss law related party disclosures key management personnel reconciliation executive remuneration disclosures required swiss law millions chf total remuneration members board directors corporate executive committee ifrs basis see table deduct bonus stock awards ifrs basis equity compensation plans ifrs basis add back bonus stock awards swiss legal basis equity compensation plans swiss legal basis total remuneration members board directors corporate executive committee swiss legal basis including social security costs board directors annual report corporate executive committee annual report bonus stock awards chairman board directors chief executive officer granted bonus stock awards lieu cashsettled bonus financial year issued end april number awards fair value per award calculated grant date roche finance report notes roche group consolidated financial statements roche group equity compensation plans members corporate executive committee received equity compensation shown following tables number rights options awards granted members corporate executive committee roche stocksettled stock appreciation rights roche restricted stock unit plan roche performance share plan contributions paid members corporate executive committee millions chf roche connect transactions former members board directors corporate executive committee pensions totalling chf million paid group former corporate executive committee members chf million defined benefit plans transactions group various defined benefit plans employees group described note list subsidiaries associates following listing group subsidiaries associates excludes subsidiaries chugai fmi well material companies notably companies inactive dormant liquidation listed companies share capital equity interest country company city millions switzerland roche holding ltd basel chf stock exchange six swiss exchange zurich valor share valor genussschein isin share ch isin genussschein ch market capitalisation chf million japan chugai pharmaceutical co ltd tokyo jpy stock exchange tokyo stock code tse isin jp market capitalisation jpy million united states foundation medicine inc cambridge usd stock exchange nasdaq stock code fmi isin us market capitalisation usd million united states senseonics holdings inc germantown usd stock exchange new york stock exchange nysemkt stock code sens isin usu market capitalisation usd million roche finance report roche group notes roche group consolidated financial statements nonlisted companies share capital equity interest country company city millions algeria roche algrie spa hydra dzd argentina productos roche sa qumica e industrial tigre ars roche diabetes care argentina sa tigre ars vanguardia en productos farmacuticos vanprofarma sa buenos aires ars australia roche diabetes care australia pty limited bella vista aud roche diagnostics australia pty limited north ryde aud roche products pty limited dee aud austria mysugr gmbh vienna eur roche austria gmbh vienna eur roche diabetes care austria gmbh vienna eur roche diagnostics gmbh vienna eur bangladesh roche bangladesh limited dhaka bdt belarus fllc roche products limited minsk usd belgium nv roche sa brussels eur roche diagnostics belgium nv brussels eur bermuda chemical manufacturing trading company limited hamilton usd hoffmannla roche products limited hamilton usd roche capital services ltd hamilton rub roche catalyst investments ltd hamilton usd roche financial investments ltd hamilton usd roche financial management ltd hamilton usd roche financial services ltd hamilton usd roche international ltd hamilton usd roche intertrade limited hamilton usd roche operations ltd hamilton usd roche services holdings ltd hamilton usd sapac corporation ltd hamilton cad syntex pharmaceuticals international limited hamilton usd bolivia roche bolivia srl santa cruz bob bosnia herzegovina roche doo farmaceutsko drustvo roche ltd pharmaceutical company sarajevo bam brazil produtos roche qumicos e farmacuticos sa paulo brl roche diabetes care brasil ltda paulo brl roche diagnostica brasil ltda paulo brl bulgaria roche bulgaria eood sofia bgn cameroon roche cameroun sarl douala xaf canada hoffmannla roche limited mississauga cad chile roche chile limitada santiago de chile clp china roche china holding ltd shanghai usd roche diagnostics hong kong limited hong kong hkd roche diagnostics shanghai ltd shanghai usd roche diagnostics suzhou limited suzhou usd roche hong kong limited hong kong hkd roche rd center china ltd shanghai usd shanghai ien pharma co ltd shanghai usd shanghai roche pharmaceuticals limited shanghai usd colombia productos roche sa bogot cop costa rica roche servicios sa heredia usd cte divoire roche cte divoire sarl abidjan xof croatia roche doo zagreb hrk czech republic roche sro prague czk denmark roche medicinalvarer og kemikalier hvidovre dkk roche diagnostics hvidovre dkk roche innovation center copenhagen hoersholm dkk dominican republic productos roche dominicana srl santo domingo dop ecuador roche ecuador sa quito usd egypt roche egypt manufacturing trading sae cairo egp roche egypt llc cairo egp rodiagnostics egypt trading sae giza egp el salvador productos roche el salvador sa de cv san salvador svc estonia roche eesti tallinn eur finland roche diagnostics oy espoo eur roche oy espoo eur france institut roche sas boulognebillancourt eur roche diabetes care france sas meylan eur roche diagnostics france sas meylan eur roche sas boulognebillancourt eur trophos sa marseille eur georgia roche georgia llc tbilisi gel roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions germany ascur versicherungsvermittlungs gmbh grenzachwyhlen eur galenus mannheim pharma gmbh mannheim eur roche beteiligungs gmbh grenzachwyhlen eur roche deutschland holding gmbh grenzachwyhlen eur roche diabetes care deutschland gmbh mannheim eur roche diabetes care gmbh mannheim eur roche diagnostics deutschland gmbh mannheim eur roche diagnostics gmbh mannheim eur roche diagnostics solutions gmbh berlin eur roche mtm laboratories ag mannheim eur roche pharma ag grenzachwyhlen eur roche pvt gmbh waiblingen eur roche real estate services mannheim gmbh mannheim eur roche registration gmbh grenzachwyhlen eur signature diagnostics gmbh potsdam eur ghana roche products ghana limited accra ghs greece roche hellas sa athens eur roche diagnostics hellas sa athens eur guatemala productos roche guatemala sociedad annima guatemala gtq honduras productos roche honduras sa tegucigalpa hnl hungary roche hungary ltd budapest huf roche services europe ltd budapest huf india roche diabetes care india private limited mumbai inr roche diagnostics india private limited mumbai inr roche products india private limited mumbai inr viewics india private limited pune inr indonesia pt roche indonesia jakarta idr iran roche pars co ltd tehran irr ireland roche ireland limited clarecastle eur roche products ireland limited dublin eur israel medingo ltd yoqneam illit ils roche pharmaceuticals israel ltd hod hasharon ils italy roche diabetes care italy spa monza eur roche diagnostics spa monza eur roche spa monza eur japan roche dc japan k k tokyo jpy roche diagnostics kk tokyo jpy jordan f hoffmannla roche ltd jordan psc amman jod kazakhstan roche kazakhstan llp almaty kzt kenya roche kenya limited nairobi kes latvia roche latvija sia riga eur lebanon roche lebanon sarl beirut lbp lithuania uab roche lietuva vilnius eur macedonia roche makedonija dooel skopje eur malaysia roche malaysia sdn bhd kuala lumpur myr roche diagnostics malaysia sdn bhd petaling jaya myr roche services asia pacific sdn bhd kuala lumpur myr syntex pharmaceuticals sdn bhd kuala lumpur myr mauritius roche products mauritius ltd quatre bornes mur mexico productos roche sa de cv mexico city mxn roche dc mxico sa de cv mexico city mxn roche servicios de mxico sa de cv mexico city mxn morocco roche sa casablanca mad myanmar roche myanmar company limited yangon usd netherlands roche diabetes care nederland bv almere eur roche diagnostics nederland bv almere eur roche finance europe bv woerden eur roche nederland bv woerden eur roche pharmholding bv woerden eur new zealand roche diagnostics nz limited auckland nzd roche products new zealand limited auckland nzd nicaragua productos roche nicaragua sa managua nio nigeria roche products limited lagos ngn norway roche diagnostics norge oslo nok roche norge oslo nok pakistan roche pakistan limited karachi pkr palestine roche pharmaceuticals palestine ltd ramallah albireh usd roche finance report roche group notes roche group consolidated financial statements share capital equity interest country company city millions panama productos roche panama sa panama city pab productos roche interamericana sa prisa panama city usd peru productos roche qumica farmacutica sa lima pen roche farma peru sa lima pen philippines roche philippines inc taguig city php poland roche diabetes care polska sp z oo warsaw pln roche diagnostics polska sp z oo warsaw pln roche polska sp z oo warsaw pln portugal roche farmacutica qumica lda amadora eur roche sistemas de diagnsticos sociedade unipessoal lda amadora eur puerto rico genentech pr inc san juan usd roche products inc ponce usd syntex puerto rico inc ponce usd romania roche romania srl bucharest ron russian federation limited liability company roche diabetes care rus moscow rub limited liability company roche diagnostics rus moscow rub roche moscow ltd moscow rub saudi arabia roche products saudi arabia llc jeddah sar serbia roche doo beograd belgrade eur singapore roche diabetes care asia pacific pte ltd singapore sgd roche diagnostics asia pacific pte ltd singapore sgd roche singapore pte ltd singapore sgd roche singapore technical operations pte ltd singapore usd slovakia roche slovensko sro bratislava eur slovenia roche farmacevtska druba doo ljubljana eur south africa kapa biosystems pty ltd cape town zar roche diabetes care south africa proprietary limited midrand zar roche products proprietary limited illovo zar south korea roche diagnostics korea co ltd seoul krw roche korea company ltd seoul krw spain emminens healthcare services sl madrid eur roche diabetes care spain sl sant cugat del valls eur roche diagnostics sl sant cugat del valls eur roche farma sa madrid eur sri lanka roche products colombo private limited colombo lkr sweden roche ab solna sek roche diagnostics scandinavia ab solna sek switzerland biopharm ag basel chf f hoffmannla roche ltd basel chf hoffmannla roche ltd basel chf intermune international ag basel chf museum tinguely ag basel chf phaor ag basel chf rabbitair ltd bachenblach chf roche capital market ltd basel chf roche chemische unternehmungen ag basel chf roche diabetes care switzerland ltd rotkreuz chf roche diabetes care ltd rotkreuz chf roche diagnostics switzerland ltd rotkreuz chf roche diagnostics international ltd rotkreuz chf roche finance ltd basel chf roche forum buonas ltd buonas chf roche glycart ltd schlieren chf roche long term foundation basel chf roche pharma switzerland ltd reinach chf syntex pharm ag rotkreuz chf tavero ag basel chf taiwan roche diagnostics ltd taipei twd roche products ltd taipei twd thailand roche diagnostics thailand limited bangkok thb roche thailand limited bangkok thb tunisia roche tunisie sa tunis tnd turkey infogenetik molekler bilgi hizmetleri anonim sirketi istanbul try roche diagnostics turkey anonim sirketi istanbul try roche mstahzarlari sanayi anonim sirketi istanbul try ukraine roche ukraine llc kiev uah roche finance report notes roche group consolidated financial statements roche group share capital equity interest country company city millions united arab emirates roche diabetes care middle east fzco dubai aed roche diagnostics middle east fzco dubai aed roche pharmaceuticals middle east fzco dubai aed united kingdom intermune holdings limited welwyn garden city gbp intermune uk limited welwyn garden city gbp kapa biosystems ltd london gbp roche diabetes care limited burgess hill gbp roche diagnostics ltd burgess hill gbp roche holding uk limited welwyn garden city gbp roche products limited welwyn garden city gbp roche registration limited welwyn garden city gbp united states adheron therapeutics inc wilmington usd anadys pharmaceuticals inc south san francisco usd ariosa diagnostics inc san jose usd bina technologies inc belmont usd bioveris corporation indianapolis usd forsight vision inc south san francisco usd genentech usa inc south san francisco usd genentech inc south san francisco usd geneweave biosciences inc los gatos usd genia technologies inc santa clara usd hlr consumer health inc little falls usd hoffmannla roche inc little falls usd igen international inc pleasanton usd igen ls llc pleasanton usd intermune inc south san francisco usd iquum inc marlborough usd kapa biosystems inc wilmington usd memory pharmaceuticals corp little falls usd mysugr inc encinitas usd roche diabetes care inc indianapolis usd roche diagnostics corporation indianapolis usd roche diagnostics hematology inc westborough usd roche diagnostics operations inc indianapolis usd roche health solutions inc indianapolis usd roche holdings inc south san francisco usd roche laboratories inc little falls usd roche molecular systems inc pleasanton usd roche palo alto llc south san francisco usd roche sequencing solutions inc pleasanton usd roche tcrc inc new york usd seragon pharmaceuticals inc south san francisco usd spring bioscience corp pleasanton usd tanox inc south san francisco usd tensha therapeutics inc south san francisco usd therapeutics human polyclonals inc south san francisco usd ventana medical systems inc tucson usd viewics inc san jose usd uruguay roche international ltd montevideo branch montevideo uyu venezuela productos roche sa caracas vef vietnam roche vietnam co ltd ho chi minh city usd share capital less local currency units roche finance report roche group notes roche group consolidated financial statements significant accounting policies consolidation policy subsidiaries companies group control group controls entity group exposed rights variable returns involvement entity ability affect returns power entity companies acquired year consolidated date control transferred group subsidiaries divested included date control passes group intercompany balances transactions resulting unrealised income eliminated full changes ownership interests subsidiaries accounted equity transactions occur control already obtained result loss control associates companies group exercises power exercise significant influence control accounted using equity method segment reporting purpose segment reporting groups corporate executive committee cec considered groups chief operating decision maker determination groups operating segments based organisation units information reported cec regular basis information provided used basis segment revenue profit disclosures reported note geographic analysis based location customers selected segment balance sheet information also routinely provided cec transfer prices operating segments set arms length basis operating assets liabilities consist property plant equipment goodwill intangible assets trade receivablespayables inventories assets liabilities provisions reasonably attributed reported operating segments nonoperating assets liabilities mainly include current deferred income tax balances postemployment benefit assetsliabilities financial assetsliabilities cash marketable securities investments debt foreign currency translation annual financial statements presented swiss francs group companies use local currency functional currency certain group companies use currencies us dollar swiss franc euro functional currency currency primary economic environment entity operates local transactions currencies initially reported using exchange rate date transaction gains losses settlement transactions gains losses translation monetary assets liabilities denominated currencies included income except qualifying cash flow hedges arise monetary items substance form part groups net investment foreign entity cases gains losses deferred comprehensive income upon consolidation assets liabilities group companies using functional currencies swiss francs translated swiss francs using yearend rates exchange income statement statement cash flows translated average rates exchange year translation differences due changes exchange rates beginning end year difference net income translated average yearend exchange rates taken directly comprehensive income revenues sales represent amounts received receivable goods supplied customers deducting trade discounts cash discounts volume rebates exclude value added taxes taxes directly linked sales revenues sale products recognised upon transfer customer significant risks rewards trade discounts cash discounts volume rebates recorded accrual basis consistent recognition related sales estimates expected sales returns chargebacks rebates including medicaid us similar rebates countries also deducted sales recorded accrued liabilities provisions deduction accounts receivable estimates based analyses existing contractual legislatively mandated obligations historical trends groups experience circumstances level sales returns hence revenues reliably measured sales recognised right return expires generally upon prescription products patients revenues recorded earned services performed single transactions split separately identifiable components reflect substance transaction necessary conversely two transactions may considered together revenue recognition purposes commercial effect understood without reference series transactions whole roche finance report notes roche group consolidated financial statements roche group cost sales cost sales includes corresponding direct production costs related production overheads goods sold services rendered royalties alliance collaboration expenses including collaboration profitsharing arrangements also reported part cost sales startup costs validation achievement normal production capacity expensed incurred research development internal research development activities expensed incurred following internal research costs incurred purpose gaining new scientific technical knowledge understanding internal development costs incurred application research findings knowledge plan develop new products commercial production development projects undertaken group subject technical regulatory uncertainties opinion management criteria capitalisation intangible assets met prior obtaining marketing approval regulatory authorities major markets postmarketing studies regulatory approval phase iv costs pharmaceuticals business generally involve safety surveillance ongoing technical support drug receives marketing approval sold may required regulatory authorities may undertaken safety commercial reasons costs postmarketing studies capitalised intangible assets opinion management generate separately identifiable incremental future economic benefits reliably measured acquired inprocess research development resources obtained inlicensing arrangements business combinations separate asset purchases capitalised intangible assets acquired asset must controlled group separately identifiable expected generate future economic benefits even uncertainty exists whether research development ultimately result marketable product consequently upfront milestone payments third parties pharmaceutical products compounds regulatory marketing approval recognised intangible assets assets acquired arrangements measured basis set intangible assets policy subsequent internal research development costs incurred postacquisition treated way internal research development costs research development embedded contracts strategic alliances group carefully assesses whether upfront milestone payments constitute funding research development work acquisition asset licensing milestone upfront receipts royalty income recognised accrual basis accordance substance respective licensing agreements collectability royalty amount reasonably assured royalties recognised revenue cash received certain group companies receive upfront milestone similar payments third parties relating sale licensing products technology revenue associated performance milestones recognised based achievement deliverables defined respective agreements upfront payments licence fees subsequent deliverables initially reported deferred income recognised income earned period development collaboration manufacturing obligation employee benefits shortterm employee benefits include wages salaries social security contributions paid annual leave sick leave profit sharing bonuses nonmonetary benefits current employees costs recognised within operating results employee rendered associated service group recognises liability profit sharing bonuses contractually obliged past practice created constructive obligation longterm employee benefits include longservice sabbatical leave longservice benefits longterm disability benefits expected costs benefits accrued period employment changes carrying value longterm employee benefit liabilities recognised within operating results termination benefits payable employment terminated group normal retirement date whenever employee accepts voluntary redundancy exchange benefits termination costs recognised earlier group longer withdraw offer benefits group recognises related restructuring costs roche finance report roche group notes roche group consolidated financial statements pensions postemployment benefits defined contribution plans group contributions recognised within operating results employee rendered associated service prepaid contributions recognised asset extent cash refund reduction future payments available defined benefit plans liability recognised balance sheet present value defined benefit obligation less fair value plan assets changes net defined benefit liability recognised occur follows recognised income statement current service costs charged appropriate income statement heading within operating results past service costs including curtailment gains losses recognised immediately general administration within operating results settlement gains losses recognised general administration within operating results net interest net defined benefit liability recognised financing costs recognised comprehensive income actuarial gains losses arising experience adjustments difference previous assumptions actually occurred changes actuarial assumptions return plan assets excluding amounts included net interest net defined benefit liability change limit recognition plan assets excluding amounts included net interest net defined benefit liability net interest net defined benefit liability comprised interest income plan assets interest cost defined benefit obligation interest effect limit recognition pension assets net interest calculated using discount rate used calculating defined benefit obligation applied net defined liability start period taking account changes contribution benefit payments pension assets liabilities different defined benefit plans offset unless group legally enforceable right use surplus one plan settle obligations plan equity compensation plans fair value equity compensation awards granted employees estimated grant date recorded expense vesting period expense charged appropriate income statement heading within operating results equitysettled plans increase equity recorded expense subsequent cash flows exercises vested awards recorded changes equity property plant equipment property plant equipment initially recorded cost purchase construction include costs directly attributable bringing asset location condition necessary capable operating manner intended management include items costs site preparation installation assembly costs professional fees net costs testing whether asset functioning properly including validation costs also included initially recorded cost construction interest borrowing costs incurred respect qualifying assets capitalised included carrying value assets property plant equipment depreciated straightline basis except land depreciated estimated useful lives major classes depreciable assets follows land improvements years buildings years machinery equipment years diagnostic instruments years office equipment years motor vehicles years parts item property plant equipment different useful lives accounted separate components estimated useful lives assets regularly reviewed necessary future depreciation charges accelerated repairs maintenance costs expensed incurred roche finance report notes roche group consolidated financial statements roche group leases group lessee finance leases exist substantially risks rewards ownership transferred group finance leases capitalised start lease fair value present value minimum lease payments lower rental obligation net finance charges reported within debt finance lease assets depreciated shorter lease term useful life interest element lease payment charged income lease term based effective interest rate method operating leases exist substantially risks rewards ownership transferred group payments made operating leases charged income straightline basis period lease group lessor certain assets mainly diagnostics instruments leased third parties finance operating lease arrangements finance lease assets reported receivables amount equal net investment lease lease income finance leases recognised term lease based effective interest rate method operating lease assets reported within property plant equipment lease income operating leases recognised lease term straightline basis business combinations business combinations accounted using acquisition method accounting date acquisition group initially recognises fair value identifiable assets acquired liabilities assumed noncontrolling interest acquired business consideration transferred measured fair value date acquisition group acquire ownership acquired business noncontrolling interests recorded either fair value proportion fair value acquired net assets attributable noncontrolling interest directly attributable acquisitionrelated costs expensed incurred within general administration expenses goodwill goodwill arises business combination excess consideration transferred acquire business underlying fair value net identified assets acquired goodwill amortised tested impairment least annually upon occurrence indication impairment intangible assets purchased patents licences trademarks intangible assets initially recorded cost assets acquired business combination initially recorded fair value available use intangible assets amortised straight line basis useful lives intangible assets reviewed impairment reporting date estimated useful life lower legal duration economic useful life estimated useful lives intangible assets regularly reviewed estimated useful lives major classes amortisable intangible assets follows product intangibles use years marketing intangibles use years technology intangibles use years impairment property plant equipment intangible assets impairment assessment carried evidence asset may impaired addition intangible assets yet available use tested impairment annually recoverable amount asset higher fair value less costs disposal value use less carrying value carrying value reduced recoverable amount reduction reported income statement impairment loss value use calculated using estimated cash flows generally fiveyear period extrapolating projections subsequent years discounted using appropriate longterm interest rate impairment loss arises useful life asset reviewed necessary future depreciation amortisation charge accelerated amount impairment loss subsequently decreases decrease related objectively event occurring impairment recognised previously recognised impairment loss reversed income statement impairment reversal roche finance report roche group notes roche group consolidated financial statements impairment goodwill goodwill assessed impairment reporting date additionally tested annually impairment goodwill allocated cashgenerating units recoverable amount cashgenerating unit higher fair value less costs disposal value use less carrying value carrying value goodwill reduced recoverable amount reduction reported income statement impairment loss acquired business included within cash generating unit permanently ceases operate treated disposal business separately identifiable goodwill generated initial acquisition business factors made goodwill entirely unrelated continuing operations cashgenerating unit goodwill deemed disposed fully impaired impairment testing methodology described note inventories inventories stated lower cost net realisable value cost finished goods work process intermediates includes raw materials direct labour directly attributable costs overheads based upon normal capacity production facilities cost determined using weighted average method net realisable value estimated selling price less cost completion selling expenses accounts receivable accounts receivable carried original invoice amount less allowances made doubtful accounts trade discounts cash discounts volume rebates similar allowances allowance doubtful accounts recorded objective evidence group able collect amounts due estimates based specific indicators ageing customer balances specific credit circumstances groups historical experience taking also account economic conditions expenses doubtful trade receivables recognised within marketing distribution expenses trade discounts cash discounts volume rebates similar allowances recorded accrual basis consistent recognition related sales using estimates based existing contractual obligations historical trends groups experience cash cash equivalents cash cash equivalents include cash hand time call current balances banks similar institutions balances reported cash equivalents readily convertible known amounts cash subject insignificant risk changes fair value maturity three months less date acquisition provisions contingencies provisions recognised legal constructive obligation incurred probably lead outflow resources reliably estimated particular restructuring provisions recognised group detailed formal plan either commenced implementation announced provisions recorded estimated ultimate liability expected arise discounted time value money material contingent liability disclosed existence obligation confirmed future events amount obligation measured reasonable reliability contingent assets recognised disclosed inflow economic benefits probable fair values fair value price would received sell asset paid transfer liability orderly transaction market participants measurement date determined reference quoted market prices use established valuation techniques option pricing models discounted cash flow method quoted prices active market available roche finance report notes roche group consolidated financial statements roche group financial instruments financial instruments classified following categories disclosed note availableforsale nonderivative financial assets either designated classified financial asset category availableforsale assets initially recorded subsequently carried fair value changes fair value recorded comprehensive income except impairments interest foreign exchange components investment derecognised cumulative gains losses equity reclassified financial income expense availableforsale assets mainly comprised marketable securities fair value hedging instruments derivative financial instruments used manage exposures foreign currency interest rate equity market credit risks derivative financial instruments initially recorded subsequently carried fair value apart derivatives designated qualifying cash flow hedging instruments changes fair value recorded financial income expense fair value designated nonderivative financial instruments designated fair value profit loss initial recognition designated fair value instruments initially recorded subsequently carried fair value changes fair value recorded income statement designated fair value instruments mainly comprised contingent consideration liabilities changes fair value recorded general administration within operating results loans receivables nonderivative financial assets fixed determinable payments quoted active market loans receivables initially recorded fair value subsequently carried amortised cost using effective interest rate method less impairment losses loans receivables mainly comprised accounts receivable cash cash equivalents financial liabilities nonderivative financial liabilities financial liabilities initially recorded fair value subsequently carried amortised cost using effective interest rate method financial liabilities mainly comprised debt trade payables financial asset derecognised contractual cash flows asset expire group transfers rights receive contractual cash flows financial assets transaction substantially risks rewards ownership financial asset transferred financial liability derecognised contractual obligations discharged cancelled expire impairment financial assets financial assets individually assessed possible impairment reporting date impairment charge recorded objective evidence impairment issuer bankruptcy default significant financial difficulty availableforsale equity securities market value original cost market value original cost sustained sixmonth period considered impaired financial assets carried amortised cost impairment charge difference carrying value recoverable amount calculated using estimated future cash flows discounted using original effective interest rate availableforsale financial assets impairment charge amount currently carried comprehensive income difference original cost fair value impairment loss reversed reversal related objectively event occurring impairment loss recognised debt securities measured amortised cost availableforsale reversal recognised income equity securities held availableforsale reversal recognised directly comprehensive income roche finance report roche group notes roche group consolidated financial statements hedge accounting group uses derivatives manage exposures foreign currency interest rate equity market credit risks instruments used may include interest rate swaps crosscurrency swaps forwards contracts options group generally limits use hedge accounting certain significant transactions qualify hedge accounting hedging relationship must meet several strict conditions documentation probability occurrence hedge effectiveness reliability measurement many transactions considered hedges economic terms required conditions met relationship qualify hedge accounting case hedging instrument hedged item reported independently hedging relationship means derivatives reported fair value changes fair value included financial income expense cash flow hedge hedge exposure variability cash flows attributable particular risk associated recognised asset liability highly probable forecast transaction could affect profit loss hedging instrument recorded fair value effective portion hedge included comprehensive income ineffective portion reported financial income expense hedging relationship hedge foreign currency risk firm commitment highly probable forecasted transaction results recognition nonfinancial item cumulative changes fair value hedging instrument recorded comprehensive income included initial carrying value nonfinancial item date recognition cash flow hedges cumulative changes fair value hedging instrument recorded comprehensive income included financial income expense forecasted transaction affects net income fair value hedge hedge exposure changes fair value recognised asset liability unrecognised firm commitment identified portion asset liability firm commitment attributable particular risk could affect profit loss hedging instrument recorded fair value hedged item recorded previous carrying value adjusted changes fair value attributable hedged risk changes fair values reported financial income expense debt debt instruments initially recorded cost proceeds received net transaction costs subsequently reported amortised cost discount net proceeds received principal value due redemption amortised duration debt instrument recognised part financing costs using effective interest rate method taxation income taxes include taxes based upon taxable profits group including withholding taxes payable distribution retained earnings within group taxes based income property capital taxes included within general administration expenses liabilities income taxes mainly withholding taxes could arise remittance retained earnings principally relating subsidiaries recognised probable earnings remitted foreseeable future amount tax liabilities uncertain accruals recorded within income tax liabilities managements best estimate ultimate liability expected arise based specific circumstances groups historical experience deferred tax assets liabilities recognised temporary differences tax bases assets liabilities carrying values deferred tax assets recognised extent probable future taxable profit available unused tax losses utilised current deferred tax assets liabilities offset income taxes levied taxation authority legally enforceable right offset deferred taxes determined based currently enacted tax rates applicable tax jurisdiction group operates equity instruments groups holdings equity instruments recorded deduction equity original purchase cost consideration received subsequent resale equity instruments movements reported changes equity instruments held groups potential conversion obligations may arise groups equity compensation plans roche finance report notes roche group consolidated financial statements roche group changes accounting policies group implemented various minor amendments existing standards interpretations material impact groups overall results financial position future new revised standards group assessed expected impacts various new revised standards interpretations mandatory january group yet applied summarised based analysis date group anticipate material impact groups overall results financial position furthermore restatements comparative results necessary new standards applied group also assessing new revised standards mandatory ifrs financial instruments group implement new standard effective january new standard replace ias financial instruments recognition measurement standard deals classification recognition measurement including impairment financial instruments also introduces new hedge accounting model new standard result increased volume disclosure information annual financial statements classification measurement financial instruments currently marketable securities classified availableforsale ias new standard equity securities classified fair value profit loss debt securities money market instrument fair value comprehensive income oci time accounts three months amortised cost group elect classify certain strategic equity investments fair value oci additionally expected reclassification within equity unrealised gains chf million net tax transferred fair value reserves retained earnings january impairment financial assets january group change methodology assessing impairment financial assets incurred loss model used ias expected credit loss model used ifrs accordance transitional provisions ifrs group restate prior periods reassess impairment allowances new approach january result allowance doubtful accounts accounts receivable expected increase chf million loss allowance financial assets increase chf million recognised together related deferred tax impact adjustment retained earnings january hedge accounting new standard introduces new hedge accounting model requires hedge accounting relationships based upon groups risk management strategy objectives discontinued relationships longer qualify hedge accounting group apply revised hedge accounting guidance hedging relationships prospectively effect january hedge accounting relationships designated previous ias guidance expected continue valid hedge accounting relationships accordance ifrs presentational changes result implementing ifrs group make number presentational changes statement comprehensive income statement changes equity note within financial income expense note within level fair values within hedge accounting roche finance report roche group notes roche group consolidated financial statements ifrs revenues contracts customers group implement new standard effective january new standard replace ias revenue ias construction contracts ifrs establishes comprehensive framework determining whether much revenue recognised also contains new requirements related presentation core principle framework revenue recognised dependent transfer promised goods services customer amount reflects consideration received exchange goods services objective standard provide fivestep approach revenue recognition includes identifying contracts customers identifying performance obligations determining transaction prices allocating transaction prices performance obligations recognising revenue performance obligations satisfied judgement need applied including making estimates assumptions multipleelement contracts identifying performance obligations constraining estimates variable consideration allocating transaction price performance obligation lease components particularly diagnostics business outlicensing agreements new standard result increased volume disclosure information annual financial statements changes introduced standard relevant roche group new standard provides new requirements additional guidance relevant group notably following areas revenue licences intellectual property including salesbased royalties constraining estimates variable consideration development milestones providing material right receive additional goods free charge certain patient access programmes may regarded separate performance obligation involving variable consideration group anticipate material impact changes new standard also clarifies allocate sales including treatment discounts element multipleelements contracts recognise sales elements contracts entered diagnostics division typically include obligations instruments including provided leasing arrangements reagents consumables services requires use estimates assumptions judgement apply guidance practice group anticipate material impact guidance outlicensing contracts pharmaceuticals division may entered obligation may include commitments research latestage development regulatory approval comarketing manufacturing may settled combination upfront payments milestone payments reimbursements services provided whether consider commitments single performance obligation separate ones even scope ifrs straightforward requires judgement depending conclusion may result revenue calculated inception either recognised spread term longer performance obligation answers new standard may different currently used new standard provides exemption salesbased royalties licences intellectual property continue recognised revenue underlying sales incurred transition approach use practical expedients group apply full retrospective method transition certain practical expedients permitted standard transition also used notably relief restate contracts began completed completed january provide disclosure requirement per ifrs paragraph comparative period amount transaction price allocated remaining performance obligations since new standard including use practical expedients modify timing amounts revenue recognised restatement necessary presentational changes result implementing ifrs group make presentational change income statement include subtotal revenue create new note revenue include increased volume required disclosure information ifrs leases group implement new standard effective january apply cumulative catchup method transition meaning comparative results restated new standard applied new standard result increased volume disclosure information annual financial statements main impact new standard bring operating leases onbalance sheet group assessing potential impact currently anticipates new standard result carrying value leased assets increased approximately chf billion lease liabilities increased similar amount date implementation application new standard result part currently reported operating lease costs recorded interest expenses given leases involved current low interest rate environment group currently expect effect material roche finance report report roche management internal control financial reporting roche group report roche management internal control financial reporting report roche management internal control financial reporting board directors management roche holding ltd responsible establishing maintaining adequate control financial reporting internal control system designed provide reasonable assurance reliability financial reporting preparation fair presentation consolidated financial statements accordance international financial reporting standards internal control systems matter well designed inherent limitations therefore even systems determined effective may prevent detect misstatements provide reasonable assurance respect financial statement preparation presentation also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate management assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso based assessment management concluded system internal control financial reporting effective december statutory auditor kpmg ag audited consolidated financial statements roche holding ltd year ended december accordance swiss auditing standards international standards auditing isa also issued report effectiveness groups system internal control financial reporting report set pages christoph franz alan hippe chairman board directors chief financial officer basel january roche finance report roche group statutory auditors report statutory auditors report general meeting roche holding ltd basel report audit consolidated financial statements opinion audited consolidated financial statements roche holding ltd subsidiaries group comprise consolidated balance sheet december consolidated income statement consolidated statement comprehensive income consolidated statement changes equity consolidated statement cash flows year ended notes consolidated financial statements including summary significant accounting policies opinion consolidated financial statements pages give true fair view consolidated financial position group december consolidated financial performance consolidated cash flows year ended accordance international financial reporting standards ifrs comply swiss law basis opinion conducted audit accordance swiss law international standards auditing isas swiss auditing standards responsibilities provisions standards described auditors responsibilities audit consolidated financial statements section report independent group accordance provisions swiss law requirements swiss audit profession well iesba code ethics professional accountants fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion key audit matters chargebacks rebates sales returns us pharmaceuticals business carrying value goodwill relating diagnostics division carrying value productrelated intangible assets provisions contingent liabilities respect litigations uncertain tax positions key audit matters matters professional judgement significance audit consolidated financial statements current period matters addressed context audit consolidated financial statements whole forming opinion thereon provide separate opinion matters roche finance report statutory auditors report roche group chargebacks rebates sales returns us pharmaceuticals business key audit matter response groups pharmaceuticals business makes sales various audit procedures included amongst others testing customers us fall certain commercial groups key controls relating deductions made governmentmandated contracts purchasing gross sales chargebacks rebates sales reimbursement arrangements significant returns including controls accrual rates used medicaid b drug discount program within managements calculations accrued liabilities group also provides right return us customers provisions deductions accounts receivable certain products return periods cases extend several years future arrangements sample basis obtained managements calculations result deductions gross amounts invoiced arriving accrued liabilities provisions accounts receivable revenue create obligations group provide deductions recalculated amounts validated customers chargebacks rebates give reasonableness key assumptions used reference credit sales returns estimated amounts deducted internal external sources including terms gross sales recorded accrued liabilities rebates applicable contracts us government pricing information provisions sales returns deduction historical chargebacks rebates historical sales accounts receivable chargebacks estimates returns levels current trends based analyses existing contractual legislatively mandated obligations historical trends groups considered accuracy managements estimates experience previous years comparing historical accrued liabilities provisions accounts receivable deductions recorded management determined accrued liabilities actual settlements also assessed changes deductions accounts receivable expected chargebacks accrual rates used within estimates including rebates predominantly medicaid chf responding increase utilisation b drug million necessary december additionally discount program comparing accrual rates provisions sales returns mainly relating products current chargeback rebate payment sales return near loss exclusivity chf million recorded trends december considered adequacy groups revenue focused area arrangements recognition accounting policies including recognition complex establishing appropriate yearend measurement deductions gross sales relating position requires significant judgement estimation chargebacks rebates sales returns related management assumptions required estimating disclosures provisions sales returns also made complicated given recent impending loss exclusivity us groups pharmaceutical products information chargebacks rebates sales returns us pharmaceuticals business refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note accounts receivable note current liabilities note provisions contingent liabilities roche finance report roche group statutory auditors report carrying value goodwill relating diagnostics division key audit matter response group goodwill chf million arising audit procedures included amongst others testing past acquisitions diagnostics division principally groups key controls surrounding carrying value corangeboehringer mannheim ventana several goodwill relating diagnostics division businesses sequencing business area goodwill assessed impairment reporting date audit goodwill included assessing groups additionally tested annually impairment budgeting procedures upon forecasts based integrity discounted cash flow models impairment testing uses projections future cash flows management used prepare valuations challenged based recent longterm forecasts approved robustness key assumptions used determine management including estimated sales volumes pricing recoverable amounts including identification allocation longterm forecasts projected five years except cgu forecast cash flows growth rates sequencing business projected ten discount rates based understanding commercial years reflecting long period required development prospects diagnostics businesses markets technologies products necessary grow operate business using valuation specialists management needs apply considerable judgement assist us evaluating assumptions methodologies allocating goodwill appropriate businesses well used management particular relating assessing future performance prospects discount rates comparing relevant assumptions cashgenerating unit cgu discount rates industry economic forecasts addition identified apply certain businesses face uncertainties technical analysed changes assumptions prior periods commercial viability leadingedge nextgeneration made assessment consistency assumptions technologies products developed performed comparison assumptions publicly available data also performed retrospective focused area light amount judgement assessment accuracy managements past estimation required history impairments recorded projections comparing historical forecasts actual results previous years amounts headroom cgus forecasts supporting carrying value goodwill exceeded usual period five years case goodwill relating sequencing business challenged management reasons made assessment managements ability forecast cash flows longer periods reasonable accuracy reviewed forecasts relating value use sequencing business impairment chf million recorded considered factors contributed impairment whether related events period also considered continued use tenyear forecast period business development also assessed whether groups disclosures sensitivity outcome impairment assessment changes key assumptions reflect risks inherent valuation goodwill information carrying value goodwill relating diagnostics division refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note goodwill roche finance report statutory auditors report roche group carrying value productrelated intangible assets key audit matter response group significant productrelated intangible assets audit procedures included amongst others testing december chf million acquired groups key controls carrying value product business combinations inlicensing arrangements related intangible assets comprise product intangibles use chf million amortised product intangibles available audit productrelated intangible assets use use chf million amortised impairment included assessing groups process key controls assessment carried productrelated intangibles identifying triggering events circumstances evidence asset may impaired evidence asset may impaired challenged intangible assets yet available use also robustness key assumptions used determine tested impairment annually recoverable amounts including forecast revenues useful lives discount rates challenge based product intangibles use chf million predominantly understanding commercial prospects individual relate acquired products launched products well relevant business areas markets key risk ability successfully commercialise operate used valuation specialists products concerned largest single intangible asset assist us evaluating assumptions methodologies arose acquisition intermune relates used management relation discount rates esbriet chf million focused product made assessments relation key inputs intangible use assessing recoverability involves projected pricing volumes products projected forecasting discounting future cash flows share therapeutic area vitro diagnostic market inherently highly judgemental headroom comparing relevant assumptions industry forecasts low key estimates assumptions include revenue growth reviewing analyst commentaries retrospective timing impact loss exclusivity discount rates assessment accuracy previous projections development commercialisation competing compared managements assumptions external data products drivers revenue growth include persistence available example case esbriet rate treatment rate market share considered higher risk impairment performed sensitivity analysis individual intangible product intangibles available use chf million asset impairment models assess level sensitivity mostly represent inprocess research development key assumptions could focus work areas assets due inherent uncertainties research assess managements allowance risk development processes intangible assets available use particularly risk impairment impairment productrelated intangibles yet available use assessment requires management make key assumptions audit included assessing reasonableness judgements clinical technical commercial managements assumptions regarding probability viability new products accordingly also focused obtaining regulatory approval comparison industry audit work areas risks include inability practice past history consideration groups achieve successful trial results obtain required clinical internal governance approval processes also regulatory approvals highly competitive business interviewed number senior research development environment therapeutic areas group commercial personnel order understand challenge significant assets research development assumptions information carrying value productrelated intangible assets refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note intangible assets roche finance report roche group statutory auditors report provisions contingent liabilities respect litigations key audit matter response pharmaceuticals industry heavily regulated discussed status significant known actual increases inherent litigation risk normal course potential litigation inhouse legal counsel management business liabilities may arise productspecific directors knowledge matters general legal proceedings antitrust challenged decisions rationale provisions held government investigations december decisions record provisions make disclosures group held provisions chf million respect legal significant matters assessed actions given highly complex nature regulatory relevant historical recent judgments passed legal cases management applies significant judgement court authorities considered legal opinion obtained considering whether much provide management external lawyers challenge basis potential exposure matter estimates could used provisions recorded disclosures made change substantially time new facts emerge group relevant also obtained formal legal case progresses confirmation groups external lawyers focused area given number complexity assessed groups internal audit reports magnitude potential exposures across group compliance logs reports prepared management judgement necessary determine whether identify actual potential noncompliance laws amounts provide andor disclose regulations specific groups business relating conduct business generally matters management concluded provisions recorded also considered adequacy completeness groups disclosures made relation contingent liabilities information provisions contingent liabilities respect litigations refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note provisions contingent liabilities roche finance report statutory auditors report roche group uncertain tax positions key audit matter response group operates across wide range different significant items challenged managements tax jurisdictions around world thus subject judgement regarding eventual resolution national occasional challenges local tax authorities including cross tax authorities double taxation conflicts pending tax border transfer pricing arrangements goods services audits estimates tax exposures assistance financing transactionrelated tax matters connection local country tax specialists significant integration investments divestments uncertain tax positions work included assessment licensing contracts areas particular focus include transfer thirdparty opinions use available pricing arrangements relating groups past experience tax authorities respective manufacturing supply chains jurisdiction additionally used tax specialists expertise assess appropriateness key amount tax liabilities uncertain group assumptions made management conclude recognises accruals reflect managements best estimate best estimate outcome outcome based facts known relevant jurisdiction group open tax transfer pricing audit approach included additional audit procedures matters various tax authorities range performed group level consider significant possible outcomes broad december uncertain tax positions particular transfer prices applied group recognised current income tax liabilities goods services intellectual property rights chf million includes accruals uncertain tax positions focused area estimates amounts tax receivable payable require significant level expertise judgement information uncertain tax positions refer following significant accounting policies note general accounting principles key accounting judgements estimates assumptions note pages financial disclosures note income taxes roche finance report roche group statutory auditors report information annual report board directors responsible information annual report information comprises information included annual report include consolidated financial statements standalone financial statements company remuneration report auditors reports thereon opinion consolidated financial statements cover information annual report express form assurance conclusion thereon connection audit consolidated financial statements responsibility read information annual report consider whether information materially inconsistent consolidated financial statements knowledge obtained audit otherwise appears materially misstated based work performed conclude material misstatement information required report fact nothing report regard responsibility board directors consolidated financial statements board directors responsible preparation consolidated financial statements give true fair view accordance ifrs provisions swiss law internal control board directors determines necessary enable preparation consolidated financial statements free material misstatement whether due fraud error preparing consolidated financial statements board directors responsible assessing groups ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate group cease operations realistic alternative auditors responsibilities audit consolidated financial statements objectives obtain reasonable assurance whether consolidated financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law isas swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis consolidated financial statements part audit accordance swiss law isas swiss auditing standards exercise professional judgment maintain professional scepticism throughout audit also identify assess risks material misstatement consolidated financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made conclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt groups ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures consolidated financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause group cease continue going concern roche finance report statutory auditors report roche group evaluate overall presentation structure content consolidated financial statements including disclosures whether consolidated financial statements represent underlying transactions events manner achieves fair presentation obtain sufficient appropriate audit evidence regarding financial information entities business activities within group express opinion consolidated financial statements responsible direction supervision performance group audit remain solely responsible audit opinion communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit consolidated financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation consolidated financial statements according instructions board directors recommend consolidated financial statements submitted approved kpmg ag ian starkey marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche group independent reasonable assurance report internal control financial reporting independent reasonable assurance report internal control financial reporting board directors roche holding ltd basel engaged board directors carry reasonable assurance engagement design implementation operating effectiveness system internal control financial reporting roche group place december management roche holding ltd assessed effectiveness system internal control financial reporting december based criteria effective internal control financial reporting described internal control integrated framework issued committee sponsoring organizations treadway commission coso responsibilities board directors management board directors management roche holding ltd responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying report roche management internal control financial reporting entitys internal control financial reporting process designed provide reasonable assurance regarding reliability financial statements prepared accordance international financial reporting standards ifrs entitys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets entity provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance applicable financial reporting framework provide reasonable assurance regarding prevention timely detection unauthorised acquisition use disposition entitys assets could material effect entitys financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate responsibilities responsibility examine design implementation effectiveness companys internal control financial reporting report thereon form independent reasonable assurance conclusion based evidence obtained conducted engagement accordance international standard assurance engagements isae assurance engagements audits reviews historical financial information issued international auditing assurance standards board standard requires plan perform procedures obtain reasonable assurance whether effective internal control financial reporting maintained material respects procedures selected depend judgement including assessment risks material misstatement design implementation effectiveness companys internal control financial reporting examination included obtaining understanding internal control financial reporting testing evaluating design implementation operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances roche finance report independent reasonable assurance report internal control financial reporting roche group independence quality control firm applies international standard quality control accordingly maintains comprehensive system quality control including documented policies procedures regarding compliance ethical requirements professional standards applicable legal regulatory requirements complied independence ethical requirements code ethics professional accountants issued international ethics standards board accountants founded fundamental principles integrity objectivity professional competence due care confidentiality professional behaviour conclusion conclusion formed basis subject matters outlined report believe evidence obtained sufficient appropriate provide basis conclusion opinion roche group maintained material respects effective internal control financial reporting december based criteria established internal control integrated framework issued committee sponsoring organizations treadway commission coso also audited accordance swiss auditing standards international standards auditing consolidated financial statements roche holding ltd year ended december report dated january expressed unqualified opinion consolidated financial statements kpmg ag ian starkey marc ziegler licensed audit expert licensed audit expert basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report roche group multiyear overview supplementary information multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report multiyear overview supplementary information roche group multiyear overview supplementary information multiyear overview statistics reported income statement millions chf sales ebitda operating profit net income attributable roche shareholders research development balance sheet millions chf noncurrent assets current assets total assets noncurrent liabilities current liabilities total liabilities net assets capital reserves attributable roche shareholders equity attributable noncontrolling interests additions property plant equipment personnel number employees end year key ratios net income attributable roche shareholders sales net income attributable roche shareholders equity research development sales current ratio equity noncontrolling interests total assets human capital return investment ratio data shares nonvoting equity securities number shares number nonvoting equity securities genussscheine total shares nonvoting equity securities total dividend millions chf earnings per share nonvoting equity security diluted chf dividend per share nonvoting equity security chf information table stated reported changes accounting policies arising changes international financial reporting standards applied retrospectively dividend proposed board directors roche finance report roche group multiyear overview supplementary information sales division millions chf pharmaceuticals diagnostics total sales geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total additions property plant equipment division millions chf pharmaceuticals diagnostics corporate total additions property plant equipment geographical area millions chf switzerland germany rest europe europe united states rest north america north america latin america japan rest asia asia africa australia oceania total roche finance report multiyear overview supplementary information roche group alternative performance measures financial information included financial review includes certain alternative performance measures apms accounting measures defined ifrs particular core results net working capital net operating assets free cash flow constant exchange rates apms used instead considered alternatives groups consolidated financial results based ifrs apms may comparable similarly titled measures disclosed companies apms presented financial review relate performance current year comparative periods core results core results allow assessment groups actual results defined ifrs underlying performance business core results concept used internal management business based ifrs results following adjustments global restructuring plans see note excluded amortisation impairment intangible assets see note impairment goodwill see note excluded acquisition accounting impacts accounting alliance arrangements business combinations see financial review excluded discontinued operations currently none excluded legal environmental cases see financial review excluded global issues outside healthcare sector beyond groups control excluded material treasury items major debt restructurings currently none excluded pension plan settlements see note excluded tax benefit recorded ifrs respect equity compensation plans ecps varies according price underlying equity replaced normalised tax benefit ifrs expense multiplied applicable tax rate see note core results concept described october investor update teleconference available download httpwwwrochecominvestorsiragendacsrhtm groups ifrs results including divisional breakdown reconciled core results tables calculation core eps also given tables additional commentary adjustment items given financial review roche finance report roche group multiyear overview supplementary information core results reconciliation millions chf alliances normali global intangibles business legal pension sation restruc amorti intangibles combi environ plan global ecp tax ifrs turing sation impairment nations mental settlements issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests core results reconciliation millions chf alliances normali global intangibles business legal pension sation restruc amorti intangibles combi environ plan global ecp tax ifrs turing sation impairment nations mental settlements issues benefit core sales royalties operating income cost sales marketing distribution research development general administration operating profit financing costs financial income expense profit taxes income taxes net income attributable roche shareholders noncontrolling interests roche finance report multiyear overview supplementary information roche group divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit divisional core results reconciliation millions chf alliances global intangibles business legal pension restruc amorti intangibles combi environ plan ifrs turing sation impairment nations mental settlements core pharmaceuticals sales royalties operating income cost sales marketing distribution research development general administration operating profit diagnostics sales royalties operating income cost sales marketing distribution research development general administration operating profit corporate general administration operating profit roche finance report roche group multiyear overview supplementary information core eps basic core net income attributable roche shareholders chf millions weighted average number shares nonvoting equity securities issue millions core earnings per share basic chf core eps diluted core net income attributable roche shareholders chf millions increase noncontrolling interests share core net income assuming outstanding chugai stock options exercised chf millions net income used calculate diluted earnings per share chf millions weighted average number shares nonvoting equity securities issue used calculate diluted earnings per share millions core earnings per share diluted chf free cash flow free cash flow used assess groups ability generate cash required conduct maintain operations also indicates groups ability generate cash finance dividend payments repay debt undertake merger acquisition activities free cash flow concept used internal management business operating free cash flow calculated based ifrs operating profit adjusted certain cash items movements net working capital capital expenditures investments property plant equipment intangible assets operating free cash flow different cash flows operating activities defined ias includes capital expenditures within responsibility divisional management excludes income taxes paid within responsibility divisional management cash outflows defined benefit plans allocated operating free cash flow based current service cost residual allocated treasury activities free cash flow calculated operating free cash flow adjusted treasury activities taxes paid free cash flow different total cash flows defined ias excludes dividend payments cash inflowsoutflows financing activities issuancerepayment debt purchasesale marketable securities cash inflowsoutflows mergers acquisitions divestments roche finance report multiyear overview supplementary information roche group operating free cash flow free cash flow calculated shown tables additional commentary adjustment items given financial review operating free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias add back income taxes paid deduct investments property plant equipment investments intangible assets disposal property plant equipment disposal intangible assets pensions postemployment benefits add back total payments defined benefit plans deduct allocation payments operating free cash flow operating items operating free cash flow free cash flow reconciliation millions chf cash flows operating activities ifrs basis accordance ias deduct investments property plant equipment investments intangible assets disposal property plant equipment disposal intangible assets interest paid operating items treasury items free cash flow roche finance report roche group multiyear overview supplementary information supplementary information used calculate divisional operating free cash flow shown table divisional operating free cash flow information millions chf pharmaceuticals diagnostics corporate group depreciation amortisation impairment depreciation property plant equipment amortisation intangible assets impairment property plant equipment impairment goodwill impairment intangible assets total adjustments add back expenses equitysettled equity compensation plans net income expense provisions net gain loss disposals noncash working capital items deduct utilisation provisions proceeds disposals total operating profit cash adjustments ebitda group use earnings interest tax depreciation amortisation ebitda either internal management reporting external communications opinion groups management operating free cash flow gives useful consistent measurement cash earnings ebitda includes many noncash items provisions allowances trade receivables inventories certain noncash entries arising acquisition accounting pension accounting convenience readers use ebitda provided table starting point uses core results already exclude amortisation impairment goodwill intangible assets ebitda using core results millions chf pharmaceuticals diagnostics corporate group ebitda core operating profit depreciation impairment property plant equipment core basis ebitda margin sales roche finance report multiyear overview supplementary information roche group net operating assets net operating assets allow assessment groups operating performance business independently financing tax activities net operating assets calculated property plant equipment goodwill intangible assets net working capital longterm net operating assets minus provisions calculation net operating assets disclosed note annual financial statements shown tables net operating assets reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net operating assets net operating assets reconciliation millions chf taxation pharmaceuticals diagnostics corporate treasury group property plant equipment goodwill intangible assets inventories provisions current income tax net liabilities deferred tax net assets defined benefit plan net liabilities marketable securities cash cash equivalents debt net assets liabilities net working capital longterm net operating assets total net operating assets net debt net debt used monitor groups overall short longterm liquidity net debt calculated sum total debt longterm shortterm less marketable securities cash cash equivalents net debt calculations including details movements current year shown table financial review roche finance report roche group multiyear overview supplementary information net working capital net working capital used assess groups efficiency utilising assets shortterm liquidity net trade working capital calculated trade receivables inventories minus trade payables net working capital calculated net trade working capital adjusted receivables payables net working capital net trade working capital calculations shown tables pharmaceuticals division diagnostics division corporate financial review constant exchange rates certain percentage changes financial review calculated using constant exchange rates cer allow assessment groups financial performance effects exchange rate fluctuations eliminated percentage changes constant exchange rates calculated using simulations reconsolidating current reported period prior period numbers constant currency exchange rates equalling average exchange rates prior year example cer change line item equivalent calculated using average exchange rate year ended december line item line item subsequently calculating change percent respect two recalculated numbers foreign exchange gains losses excluded calculation cer growth rates earnings per share calculations countries significant devaluation local currency current year simulations use average exchange rate current year instead prior year avoid cer growth rates artificially inflated roche finance report roche securities roche group roche securities price development share chf roche share swiss market index rebased price development nonvoting equity security genussschein chf roche nonvoting equity security swiss market index rebased price development american depositary receipt adr usd roche adr sp index rebased eight roche american depositary receipts adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july information tables restated change ratio adrs effective january change ratio adrs effective january change ratio adrs effective february roche finance report roche group roche securities number shares nonvoting equity securities number shares nominal value chf number nonvoting equity securities genussscheine nominal value total number shares nonvoting equity securities genussscheine held total issue data per share nonvoting equity security chf earnings basic earnings diluted core earnings basic core earnings diluted equity attributable roche shareholders dividend c stock price share b opening high low yearend stock price nonvoting equity security genussschein b opening high low yearend market capitalisation millions chf yearend key ratios yearend dividend yield shares dividend yield nonvoting equity securities genussscheine priceearnings shares priceearnings nonvoting equity securities genussscheine nonvoting equity security genussschein confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value shares participation certificate capital shares nonvoting equity securities listed six swiss exchange roche holding ltd restrictions ownership shares nonvoting equity securities b stock price data reflect daily closing prices c dividend proposed board directors ticker symbols share nonvoting equity security american depositary receipt adr six swiss exchange ro rog bloomberg ro sw rog vx rhhby us reuters ros rogvx rhhbypk roche finance report roche holding ltd basel financial statements notes financial statements summary significant accounting policies significant shareholders shareholders equity fulltime equivalent employees contingent liabilities board executive shareholdings appropriation available earnings statutory auditors report general meeting roche holding ltd basel roche finance report roche holding ltd basel financial statements financial statements balance sheet millions chf december december current assets cash cash equivalents marketable securities accounts receivable group companies shortterm loans group companies current receivables total current assets noncurrent assets longterm loans group companies investments total noncurrent assets total assets shortterm liabilities accounts payable group companies interestbearing liabilities group companies shortterm liabilities total shortterm liabilities longterm liabilities provisions total longterm liabilities total liabilities shareholders equity share capital nonvoting equity securities genussscheine pm pm legal retained earnings general legal retained earnings voluntary reserves retained earnings free reserve special reserve available earnings balance brought forward previous year net income year total shareholders equity total shareholders equity liabilities pm pro memoria nonvoting equity securities nominal value roche finance report financial statements roche holding ltd basel income statement millions chf year ended december income income investments dividend income financial income interest income loans group companies income marketable securities guarantee fee income group companies income total income expenses administration expenses expenses financial expenses direct taxes total expenses net income roche finance report roche holding ltd basel notes financial statements notes financial statements summary significant accounting policies basis preparation financial statements roche holding ltd basel company prepared accordance provisions swiss law accounting financial reporting nd title swiss code obligations co prescribed law significant accounting principles applied described company prepared consolidated financial statements accordance recognised accounting standard international financial reporting standards accordance co company decided forgo presenting additional information audit fees notes well cash flow statement valuation methods translation foreign currencies marketable securities reported lower cost market value financial assets including investments reported cost less appropriate writedowns equity instruments recognised cost deducted equity time purchase equity instruments sold gain loss recognised income statement assets liabilities denominated foreign currencies translated swiss francs using yearend rates exchange except investments translated historical rates transactions year denominated foreign currencies translated exchange rates effective relevant transaction dates resulting exchange gains losses recognised income statement exception unrealised gains deferred investments direct indirect investments company listed note roche group annual financial statements listing excludes subsidiaries chugai fmi well material companies notably companies inactive dormant liquidation ownership interests equal voting rights taxes direct taxes include corporate income capital taxes shareholders equity share capital previous year share capital amounts chf million share capital consists bearer shares nominal value chf included equity nonvoting equity securities genussscheine part share capital confer voting rights however nonvoting equity security confers rights shares participate available earnings remaining proceeds liquidation following repayment nominal value share capital participation certificates roche finance report notes financial statements roche holding ltd basel equity instruments december company hold roche shares none company purchase roche shares company sell roche shares roche shares sold average sales price chf per share net gain chf million dividend income received chf million companys subsidiaries meet definitions requirements article b co hold equity instruments within roche group annual financial statements entities mainly foundations included consolidation qualify subsidiaries article b co movement recognised amounts millions chf legal voluntary reserves retained earnings share retained free special available equity total capital earnings reserve reserve earnings instruments equity january net income dividends transactions equity instruments december net income dividends transactions equity instruments december net income dividends transactions equity instruments december contingent liabilities guarantees company issued guarantees certain bonds notes commercial paper credit facilities group companies nominal amount outstanding december chf billion chf billion described note roche group annual financial statements significant shareholders shares company bearer shares reason company keep register shareholders following figures based information shareholders shareholder validation check annual general meeting march information available company roche finance report roche holding ltd basel notes financial statements controlling shareholders december based information supplied group shareholder group pooled voting rights owned shares represented issued shares group consisted ms vera michalskihoffmann ms maja hoffmann mr andr hoffmann dr andreas oeri ms sabine duschmaloeri ms catherine oeri dr jrg duschmal mr lukas duschmal charitable foundation wolf shareholder pooling agreement existed since figures include shares without pooled voting rights held outside group individual members group ms maja oeri formerly member pool holds shares representing voting rights independently pool december based information supplied group shares shares owned novartis holding ag basel participation fulltime equivalent employees annual average number fulltime equivalent employees exceed ten people board executive shareholdings board directors directors mr andr hoffmann dr andreas oeri certain members founders families closely associated belong shareholder group pooled voting rights end group held shares issued shares detailed information group given note addition end year members board directors persons closely associated held shares nonvoting equity securities genussscheine shown table shareholdings members board directors nonvoting equity securities shares genussscheine ch franz hoffmann p baschera na na j bell j brown p bulcke hauser na na rp lifton e oeri b poussot schwan b c suessmuth dyckerhoff c c pr voser total include shares held shareholder group pooled voting rights b member corporate executive committee dr schwans shareholdings disclosed tables c jointly held close relative close relatives hauser held nonvoting equity securities genussscheine na e rp lifton held roche american depositary receipts adrs none eight adrs equivalent one nonvoting equity security genussschein adrs traded us overthecounter market since july roche finance report notes financial statements roche holding ltd basel corporate executive committee members corporate executive committee persons closely associated held shares nonvoting equity securities shown table shareholdings members corporate executive committee nonvoting equity securities shares genussscheine sschwan rdiggelmann ahippe ga keller b doday ca wilbur total equity compensation awards ssars rsus roche performance share plan b close relatives dr keller held roche shares roche shares december members corporate executive committee held stocksettled stock appreciation rights ssars shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages ssars awards held december year issue total sschwan rdiggelmann ahippe ga keller doday ca wilbur total cec strike price chf expiry date mar mar mar mar mar mar feb december members corporate executive committee held restricted stock units rsus shown table terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages rsus remuneration component corporate executive committee replaced awarding corresponding performance share plan psp awards rsu awards vested recipient three years thereafter nonvoting equity securities may remain blocked ten years rsu awards held december year issue total sschwan na na rdiggelmann na na ahippe na na ga keller na na doday na na ca wilbur na na total cec na na roche finance report roche holding ltd basel notes financial statements december members corporate executive committee shown table held psp awards psp performance cycles terms vesting conditions awards disclosed note roche group annual financial statements additional supplementary information remuneration report included annual report pages award result zero two nonvoting equity securities shares value adjustment depending upon achievement performance targets discretion board directors vesting nonvoting equity securities shares may remain blocked ten years end cycle performance targets achieved accordingly participants received none originally targeted shares total target number awards outstanding performance cycles december shown table roche performance share plan awards held december psp psp schwan r diggelmann hippe ga keller oday ca wilbur total cec allocation date feb feb information relating number value rights options awards granted employees roche group members board directors corporate executive committee company disclosed note note roche group annual financial statements roche finance report appropriation available earnings roche holding ltd basel appropriation available earnings proposals annual general meeting chf available earnings balance brought forward previous year net profit year total available earnings appropriation available earnings distribution ordinary dividend chf gross per share nonvoting equity security genussschein chf last year total appropriation available earnings carried forward account roche finance report roche holding ltd basel statutory auditors report statutory auditors report general meeting roche holding ltd basel report audit financial statements opinion audited financial statements roche holding ltd comprise balance sheet december income statement year ended notes financial statements including summary significant accounting policies opinion financial statements pages year ended december comply swiss law companys articles incorporation basis opinion conducted audit accordance swiss law swiss auditing standards responsibilities provisions standards described auditors responsibilities audit financial statements section report independent entity accordance provisions swiss law requirements swiss audit profession fulfilled ethical responsibilities accordance requirements believe audit evidence obtained sufficient appropriate provide basis opinion report key audit matters based circular federal audit oversight authority key audit matters matters professional judgement significance audit financial statements current period determined key audit matters communicate report responsibility board directors financial statements board directors responsible preparation financial statements accordance provisions swiss law companys articles incorporation internal control board directors determines necessary enable preparation financial statements free material misstatement whether due fraud error preparing financial statements board directors responsible assessing entitys ability continue going concern disclosing applicable matters related going concern using going concern basis accounting unless board directors either intends liquidate entity cease operations realistic alternative auditors responsibilities audit financial statements objectives obtain reasonable assurance whether financial statements whole free material misstatement whether due fraud error issue auditors report includes opinion reasonable assurance high level assurance guarantee audit conducted accordance swiss law swiss auditing standards always detect material misstatement exists misstatements arise fraud error considered material individually aggregate could reasonably expected influence economic decisions users taken basis financial statements roche finance report statutory auditors report roche holding ltd basel part audit accordance swiss law swiss auditing standards exercise professional judgement maintain professional scepticism throughout audit also identify assess risks material misstatement financial statements whether due fraud error design perform audit procedures responsive risks obtain audit evidence sufficient appropriate provide basis opinion risk detecting material misstatement resulting fraud higher one resulting error fraud may involve collusion forgery intentional omissions misrepresentations override internal control obtain understanding internal control relevant audit order design audit procedures appropriate circumstances purpose expressing opinion effectiveness internal control evaluate appropriateness accounting policies used reasonableness accounting estimates related disclosures made c onclude appropriateness board directors use going concern basis accounting based audit evidence obtained whether material uncertainty exists related events conditions may cast significant doubt entitys ability continue going concern conclude material uncertainty exists required draw attention auditors report related disclosures financial statements disclosures inadequate modify opinion conclusions based audit evidence obtained date auditors report however future events conditions may cause entity cease continue going concern communicate board directors relevant committee regarding among matters planned scope timing audit significant audit findings including significant deficiencies internal control identify audit also provide board directors relevant committee statement complied relevant ethical requirements regarding independence communicate relationships matters may reasonably thought bear independence applicable related safeguards matters communicated board directors relevant committee determine matters significance audit financial statements current period therefore key audit matters describe matters auditors report unless law regulation precludes public disclosure matter extremely rare circumstances determine matter communicated report adverse consequences would reasonably expected outweigh public interest benefits communication report legal regulatory requirements accordance article para item co swiss auditing standard confirm internal control system exists designed preparation financial statements according instructions board directors confirm proposed appropriation available earnings complies swiss law companys articles incorporation recommend financial statements submitted approved kpmg ag ian starkey marc ziegler licensed audit expert licensed audit expert auditor charge basel january kpmg ag viaduktstrasse po box ch basel kpmg ag subsidiary kpmg holding ag member kpmg network independent firms affiliated kpmg international cooperative kpmg international swiss legal entity rights reserved roche finance report published cautionary statement regarding forwardlooking statements f hoffmannla roche ltd annual report contains certain forwardlooking statements group communications forwardlooking statements may identified words basel switzerland believes expects anticipates projects intends tel seeks estimates future similar expressions wwwrochecom discussion among things strategy goals plans intentions various factors may cause actual results differ orderdownload publications materially future reflected forwardlooking internet rochecompublications statements contained annual report among others email baselwarehouseservicesrochecom pricing product initiatives competitors legislative fax regulatory developments economic conditions delay inability obtaining regulatory approvals bringing products media relations market fluctuations currency exchange rates general tel financial market conditions uncertainties discovery email rochemediarelationsrochecom development marketing new products new uses existing products including without limitation negative results clinical investor relations trials research projects unexpected side effects pipeline tel marketed products increased government pricing pressures email investorrelationsrochecom interruptions production loss inability obtain adequate protection intellectual property rights litigation corporate sustainability committee loss key executives employees adverse tel publicity news coverage email corporatesustainabilityrochecom statement regarding earnings per share growth profit next annual general meeting forecast interpreted mean roches march earnings earnings per share subsequent period necessarily match exceed historical published earnings earnings per share roche trademarks legally protected links thirdparty pages provided convenience express opinion content thirdparty pages expressly disclaim liability thirdparty information use roche finance report published german english case doubt differences interpretation english version shall prevail german text reporting consists actual annual report finance report contains annual financial statements consolidated financial statements regards content management report per articles incorporation consists aforementioned reports exception remuneration report printed nonchlorine bleached fsccertified paperf hoffmannla roche ltd basel switzerland trademarks legally protected wwwrochecom e roche finance report finance report